Evidence-Based Review: Supplements for Female Sexual Function A Practical Guide for Integrative and Functional Medicine Perspective Edited by Yoon Hang Kim MD MPH About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified integrative medicine physician with over 20 years of clinical experience. He completed his integrative medicine fellowship at the University of Arizona under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative/holistic medicine. Through his telemedicine practice, Dr. Kim specializes in autoimmune conditions, chronic pain, integrative oncology, and complex conditions including fibromyalgia, chronic fatigue, MCAS, and mold toxicity. He is the author of three books and more than 20 articles, and has helped establish integrative medicine programs at institutions nationwide. Professional:   www.yoonhangkim.com  | Clinical:   www.directintegrativecare.com Evidence-Based Review: Supplements for Female Sexual Function A Practical Guide for Integrative and Functional Medicine Perspective Edited by Yoon Hang Kim MD MPH Introduction: Why This Matters Let's be honest—female sexual dysfunction is one of those topics that often gets pushed to the margins of clinical conversations. Yet it affects roughly 40% of women worldwide and can profoundly impact quality of life, intimate relationships, and overall well-being. In my two decades of clinical practice, I've found that many women feel dismissed when they bring up concerns about low libido, difficulty with arousal, or other sexual health issues. This is where integrative medicine and functional medicine approaches shine. Rather than simply prescribing a pill and sending patients on their way, we have the opportunity to explore root causes—hormonal imbalances, chronic stress, nutritional deficiencies, relationship dynamics, and mental health factors like anxiety and depression. Sometimes the solution is a supplement. Often, it's a combination of targeted interventions, lifestyle changes, and addressing psychological contributors. What follows is my synthesis of the current evidence on natural supplements for female sexual function. I've tried to be both thorough and practical—giving you the data you need to have informed conversations with your patients while being honest about the limitations of the research. The Current State of Evidence The landmark 2021 meta-analysis by Sha'ari and colleagues, published in Phytomedicine , remains our best starting point. Their systematic review of 20 studies identified Tribulus terrestris  and Panax ginseng  as showing the most robust evidence for improving female sexual function. Since then, we've seen additional research on ashwagandha, saffron, fenugreek, and maca—though the evidence quality remains predominantly low to moderate across the board. Before diving into individual supplements, I want to emphasize something important: substantial placebo effects (up to 40% in some trials) complicate interpretation of these studies. Sexual function is deeply tied to psychological factors, expectations, and relationship dynamics. This doesn't mean supplements don't work—it means we need to be thoughtful about setting realistic expectations with patients. Tribulus terrestris: The Strongest Evidence If I had to pick one supplement with the most compelling data, it would be Tribulus terrestris . The Sha'ari meta-analysis found large effect sizes for overall sexual function (SMD = 1.12), sexual desire (SMD = 1.08), arousal (SMD = 1.03), and orgasm (SMD = 0.51)—all statistically significant compared to placebo. What the Individual Trials Show A double-blind RCT with 67 premenopausal women with hypoactive sexual desire disorder found that just 7.5 mg/day of Tribulus extract for 4 weeks produced significant improvements in total FSFI scores and the desire domain (p < 0.001). That's a remarkably low dose showing meaningful effects. For postmenopausal women, an RCT using 750 mg/day for 120 days showed improvements in both FSFI and Sexual Quotient scores. Interestingly, serum testosterone levels didn't significantly change—suggesting the mechanism may not be straightforward testosterone modulation as many assume. An open-label assessment of 120 women found that 88% showed improvement in total FSFI scores, with DHEA levels increasing significantly while testosterone remained stable. This hints at adrenal pathway involvement rather than direct gonadal effects. How It Probably Works Tribulus contains protodioscin, a steroidal saponin that may influence the hypothalamic-pituitary axis, potentially affecting LH and FSH secretion. The DHEA elevation suggests adrenal modulation. Animal studies hint at effects on follicular development, though human data is limited. Practical Recommendations Typical dosing ranges from 250–750 mg/day in divided doses for 4–16 weeks. Side effects are generally mild GI symptoms (gastric discomfort, occasional reflux). The 2020 systematic review by Martimbianco emphasized that evidence certainty remains "very low"—so shared decision-making with patients about realistic expectations is essential. Ashwagandha: The Stress-Libido Connection Ashwagandha ( Withania somnifera ) is one of my go-to recommendations, particularly for women where stress seems to be suppressing libido. We now have three well-designed RCTs specifically examining its effects on female sexual function. The Clinical Evidence 2015 Pilot Study (n=50): Using 600 mg/day of high-concentration root extract (HCARE) for 8 weeks, researchers found significant improvements versus placebo in total FSFI (p < 0.001), arousal, lubrication, orgasm, and satisfaction. Notably, the desire domain did not  reach significance—an important nuance for patient counseling. 2022 KSM-66 Study (n=80): This trial showed statistically significant improvement in all  FSFI subscales including desire (p < 0.0001). Quality of life scores also improved. The KSM-66 extract may have advantages over other formulations. 2025 RCT (n=62): The most recent study confirmed improvements in FSFI (p = 0.002), Perceived Stress Scale (p = 0.0009), and SF-12 quality of life (p = 0.044). The correlation between stress reduction and sexual function improvement supports the adaptogenic mechanism. Why It Works Ashwagandha's adaptogenic properties reduce cortisol and normalize HPA axis function. Chronic stress is a major libido killer—elevated cortisol suppresses gonadal function and shifts the body into "survival mode" rather than "thriving mode." By addressing the stress response, ashwagandha may restore conditions favorable to healthy sexual function. Its anxiolytic and antidepressant effects likely contribute as well. Dosing and Safety Standard dosing is 300–600 mg/day of standardized root extract for 8+ weeks. Side effects are rare and mild (occasional nausea, drowsiness). Long-term safety studies in rats showed a no-observed-adverse-effect level of 2000 mg/kg/day, supporting a favorable safety profile at human therapeutic doses. Saffron: Especially for SSRI-Induced Dysfunction Saffron ( Crocus sativus ) deserves special attention for women experiencing antidepressant-induced sexual dysfunction—a frustratingly common clinical scenario. A meta-analysis found significant effects on arousal (p = 0.028) and lubrication (p = 0.03). Key Studies A 2022 three-center RCT enrolled 68 women with severe FSD. Those receiving 15 mg saffron twice daily showed 62% improvement from baseline at 6 weeks, with superiority over placebo in desire, lubrication, and satisfaction domains. The time × treatment interaction favored saffron (p = 0.050). For fluoxetine-induced dysfunction specifically, earlier studies showed saffron improved arousal, lubrication, and pain—domains particularly affected by SSRIs. A 2024 trial combining saffron (30 mg/day) with vitamin E (50 mg) showed overall sexual function improvement (AMD 4.6, p < 0.001), with benefits sustained 4 weeks post-intervention. Mechanism Saffron's bioactive compounds (crocin, safranal) enhance dopamine and glutamate neurotransmission—potentially counteracting SSRI effects on these pathways. Its antidepressant and anxiolytic properties address psychological aspects, while antinociceptive effects may reduce pain-related discomfort. Nitric oxide release promotes genital blood flow. Practical Use Typical dosing is 15–30 mg/day for 4–8 weeks. Within therapeutic ranges, saffron is well-tolerated. Cost can be a barrier given saffron's expense, but standardized supplements are more affordable than culinary-grade saffron. Panax Ginseng: Meta-Analytic Support Korean red ginseng has solid meta-analytic support for arousal (SMD = 0.54, p = 0.014) and desire (SMD = 0.59, p < 0.001) in the Sha'ari analysis. Clinical Data A crossover RCT with 32 menopausal women found Korean red ginseng 3 g/day significantly improved sexual arousal (p = 0.006), with benefits in desire, lubrication, orgasm, and satisfaction. A premenopausal study showed FSFI improvements after 8 weeks, though the difference versus placebo didn't reach significance—highlighting substantial placebo effects in this population. How It Works Ginsenosides enhance nitric oxide synthesis in vascular endothelium, producing vasodilatory effects that improve genital blood flow. Antioxidant protection of vascular endothelium and potential modulation of dopamine and acetylcholine neurotransmitters may also contribute. Dosing Standard dosing is 1–3 g/day of Korean red ginseng for 8+ weeks. Generally well-tolerated; occasional gastric discomfort reported. Maca: Best for SSRI-Induced Dysfunction Maca root ( Lepidium meyenii ) shows its strongest effects in women with SSRI-induced sexual dysfunction—a niche where we desperately need options. The Evidence A dose-finding pilot study found 3 g/day maca (versus 1.5 g/day) significantly improved ASEX and MGH-SFQ scores in women with SSRI-induced dysfunction, with libido specifically improving on the ASEX item (p = 0.028). The higher dose appears important. A double-blind follow-up showed higher remission rates with maca versus placebo, with postmenopausal women showing particularly robust responses—though researchers noted this might relate to age rather than menopausal status specifically. Mechanism Mystery Interestingly, maca doesn't appear to have direct androgenic activity and doesn't significantly affect serum reproductive hormone levels. The mechanism remains unclear but may involve non-hormonal pathways affecting energy, mood, and central nervous system function. Sometimes the clinical effect matters more than understanding exactly why it works. Practical Points Use 1.5–3 g/day for 6–12 weeks. The higher dose (3 g/day) appears more effective. Maca is generally well-tolerated with minimal side effects. Available in various forms including gelatinized powder, which may be easier to digest. Fenugreek: Hormonal Effects Fenugreek ( Trigonella foenum-graecum ) is interesting because it actually moves hormones—something most botanicals don't reliably do. Clinical Studies Libifem® Study (n=80): 600 mg/day of standardized fenugreek seed extract in healthy menstruating women with self-reported low libido significantly increased estradiol and free testosterone levels versus placebo. Sexual desire and arousal improved. FenuSMART Study (n=48): 250 mg twice daily for 42 days showed 41.6% of participants reporting relief from sexual problems and irritability, with significant increases in estradiol (p = 0.040), free testosterone (p = 0.025), and total testosterone (p = 0.012). Mechanism Fenugreek contains saponins with phytoestrogenic activity. Effects appear stronger in women with suboptimal baseline hormone levels—suggesting it may work by normalizing deficiencies rather than pushing levels supraphysiological. This makes it potentially useful for perimenopause and hormone balance optimization. Dosing Typical dosing is 500–600 mg/day of standardized extract for 6–8 weeks. Generally well-tolerated. May cause maple syrup-like body odor in some individuals (harmless but can be surprising for patients). L-Arginine Combinations: Variable Results A 2021 systematic review by Cieri-Hutcherson evaluated seven studies on L-arginine for HSDD. Six of seven reported improvements in FSFI scores—but the devil is in the details. Key Findings Combination products like ArginMax (L-arginine with Panax ginseng, Ginkgo biloba, damiana, vitamins and minerals) show more consistent benefits than L-arginine monotherapy. ArginMax studies showed 73.5% of women improved in satisfaction with overall sex life versus 37.2% with placebo (p < 0.01). Results vary by menopausal status: premenopausal women showed improved desire and satisfaction; perimenopausal women showed improved intercourse frequency and vaginal dryness; postmenopausal women primarily showed increased desire (51% vs 8%, p = 0.008). In cancer survivors, ArginMax didn't improve sexual function but did improve overall quality of life—a reminder that sexual function improvements don't always follow general well-being improvements. Practical Notes L-arginine enhances nitric oxide production for improved blood flow. Combination products likely work through multiple mechanisms. ArginMax has been shown to exhibit no estrogenic activity on bioassay, making it suitable for women avoiding hormone therapy. Standard dosing is 3 capsules twice daily for 4–12 weeks. Intranasal Oxytocin: Not Ready for Primetime Despite theoretical appeal, intranasal oxytocin hasn't lived up to expectations. A key randomized trial by Muin and colleagues (2015) found no significant superiority over placebo in improving FSFI scores in women with HSDD. The placebo group showed up to 40% improvement—highlighting just how powerful expectation and attention effects can be in sexual function research. While endogenous oxytocin naturally rises during arousal and orgasm and contributes to bonding and satisfaction, exogenous administration doesn't reliably translate to improved desire or arousal. Some observational data suggest indirect enhancements through partner dynamics, but controlled evidence is lacking. Bottom line: I don't currently recommend intranasal oxytocin for low libido treatment. The Elephant in the Room: Mind-Body Interventions Here's something that might surprise you: psychological and lifestyle interventions often show effect sizes comparable or superior  to supplements—and with arguably better evidence quality. Mindfulness-Based Therapy The research by Brotto and Basson (2014) found that group mindfulness therapy significantly improved sexual desire (the primary outcome), arousal, lubrication, satisfaction, and overall function. Increases in mindfulness skills and reductions in depressive symptoms predicted improvements in desire—suggesting mechanism. A 2025 RCT of the eSense online intervention found both CBT and mindfulness-based therapy arms showed large effect sizes versus waitlist: desire/arousal (d > 0.90), sexual distress (d < −0.62), and overall function (d = 1.20–1.23). Effects maintained at 6-month follow-up. These are impressive numbers that rival or exceed most supplement trials. Why This Matters for Integrative Practice Sexual desire is profoundly psychological. Chronic stress, relationship dynamics, past trauma, body image concerns, and negative sexual beliefs all contribute to low libido. Supplements can play a supportive role, but addressing these psychological factors often produces the most durable results. Consider cognitive behavioral sex therapy, sensate focus exercises, communication training, and addressing avoidance behaviors as part of comprehensive treatment. Putting It All Together: Evidence Summary Strongest Evidence (Meta-analytic Support) Tribulus terrestris: desire, arousal, orgasm, overall function Panax ginseng: desire, arousal Moderate Evidence (Multiple RCTs) Ashwagandha: arousal, lubrication, orgasm, satisfaction (especially with stress component) Saffron: arousal, lubrication, desire (especially for SSRI-induced dysfunction) Fenugreek: desire, hormonal effects Limited Evidence (Fewer/Smaller Trials) Maca: best for SSRI-induced dysfunction, postmenopausal women L-arginine combinations: variable by population Insufficient Evidence Ginkgo biloba: inconsistent results Intranasal oxytocin: no superiority over placebo Honest Assessment of Limitations I want to be transparent about what we don't know. Most trials have small sample sizes (30–100 participants), heterogeneous populations, and variable dosing regimens that make direct comparisons difficult. Placebo effects are substantial—sometimes 40% of placebo groups show improvement. Many studies have moderate-to-high risk of bias, and industry funding is common. Most trials run only 4–12 weeks, leaving long-term efficacy and safety uncertain. Does this mean supplements don't work? Not necessarily. It means we need to be humble about the strength of evidence and realistic with patients about what to expect. Clinical Recommendations for Practice Start with comprehensive assessment: Rule out medical conditions, medication effects, relationship factors, and psychological contributors. Consider functional medicine labs to identify underlying hormonal imbalances or nutritional deficiencies. Practice shared decision-making: Discuss the limited evidence quality, uncertainties, and set realistic expectations. Some patients will respond dramatically; others may see modest or no benefit. Consider combination approaches: Supplements work best as adjuncts to lifestyle modifications (stress reduction, exercise, sleep optimization) and psychological interventions (mindfulness, CBT, couples counseling). Choose quality products: Recommend standardized extracts from reputable manufacturers with third-party testing. Product quality varies enormously in the supplement industry. Allow adequate trial duration: Give supplements 8–12 weeks before assessing efficacy. Many patients expect faster results—manage these expectations upfront. Monitor for interactions: Be aware of potential herb-drug interactions, particularly with hormonal therapies, antidepressants, and blood thinners. Meet Dr. Yoon Hang Kim MD MPH At Direct Integrative Care, Dr. Kim is dedicated to guiding you on your path to wellness through a deeply personalized and supportive approach. We focus on integrative medicine, looking beyond symptoms to uncover the root causes of chronic conditions and develop a treatment plan tailored specifically to your unique health journey. By combining compassionate care with innovative therapies, our goal is to empower you with the knowledge and tools needed to achieve lasting health. We invite you to explore our website to learn more about how our patient-centered practice can help you find balance and vitality.  Yoon Hang Kim MD Integrative & Functional Medicine Physician Virtual Practice Serving IA, IL, MO, FL, GA, and TX www.directintegrativecare.com Key References 1. Sha'ari N, et al. Beneficial effects of natural products on female sexual dysfunction: A systematic review and meta-analysis. Phytomedicine . 2021;93:153760. PMID: 34638031 2. Martimbianco ALC, et al. Tribulus terrestris for female sexual dysfunction: A systematic review. Rev Bras Ginecol Obstet . 2020;42(7):427-435. PMID: 32736394 3. Dongre S, et al. Efficacy and safety of ashwagandha root extract in improving sexual function in women: A pilot study. Biomed Res Int . 2015;2015:284154. PMID: 26504795 4. Ajgaonkar A, et al. Efficacy and safety of ashwagandha root extract for improvement of sexual health in healthy women. Cureus . 2022;14(10):e30787. PMID: 36447681 5. Kashani L, et al. Crocus sativus (saffron) in the treatment of female sexual dysfunction: A three-center RCT. Avicenna J Phytomed . 2022;12(3):257-268. PMID: 36186931 6. Brotto LA, Basson R. Group mindfulness-based therapy significantly improves sexual desire in women. Behav Res Ther . 2014;57:43-54. PMID: 24814472 7. Cieri-Hutcherson NE, et al. Systematic review of L-arginine for hypoactive sexual desire disorder in women. Pharmacy (Basel) . 2021;9(2):71. 8. Oh KJ, et al. Effects of Korean red ginseng on sexual arousal in menopausal women. J Sex Med . 2010;7(4):1469-1477. 9. Rao A, et al. Influence of fenugreek seed extract on testosterone, estradiol and sexual function in healthy menstruating women. Phytother Res . 2015;29(8):1123-1130. 10. Dording CM, et al. A double-blind placebo-controlled trial of maca root for antidepressant-induced sexual dysfunction. Evid Based Complement Alternat Med . 2015;2015:949036. 11. Muin DA, et al. Effect of long-term intranasal oxytocin on sexual dysfunction: A randomized trial. Fertil Steril . 2015;104(3):612-619. 12. Ranjbar H, Ashrafizaveh A. Effects of saffron on sexual dysfunction among men and women: A systematic review and meta-analysis. Avicenna J Phytomed . 2019;9(5):419-427. Disclaimer: This review is for educational purposes only. Individual responses to supplements vary significantly. Consultation with a qualified healthcare professional is essential before initiating any supplement or therapy for sexual dysfunction. Supplements may interact with medications or underlying conditions.

Using LDN to Treat Neuropathy Edited by Yoon Hang Kim MD MPH About Dr. Kim Dr. Yoon Hang “John” Kim is a fellowship-trained integrative and functional medicine physician with over 20 years of experience. He completed a residential fellowship in integrative medicine at the University of Arizona under Dr. Andrew Weil and is a 2024 Functional Medicine for All scholarship recipient from the Institute for Functional Medicine. After serving as Chief Wellness Officer at a rural community hospital in Illinois, Dr. Kim now provides virtual integrative and functional medicine care, expanding access to personalized, evidence-based treatment nationwide. His root-cause approach combines advanced functional lab testing with lifestyle medicine, nutrition, movement, mindfulness, and complementary therapies. Board-certified in preventive medicine, medical acupuncture, and integrative and holistic medicine, Dr. Kim has been a faculty member, consultant, and founder of an academic integrative health program. His clinical focus includes autoimmune disease, chronic pain, gastrointestinal disorders, integrative oncology, fibromyalgia, chronic fatigue syndrome, long COVID, and mold-related illness. He is the author of two books and more than 20 publications. Professional Inquiries:   www.yoonhangkim.com Clinical Inquiries:   www.directintegrativecare.com Introduction Neuropathy—damage or dysfunction of peripheral nerves—represents a significant clinical challenge due to its prevalence and impact on quality of life. Conventional treatments, including anticonvulsants, antidepressants, and opioids, often provide incomplete relief and carry significant side effects. Low-dose naltrexone (LDN), an off-label use of naltrexone at doses typically ranging from 1 to 5 mg daily, has emerged as a promising option within integrative and functional medicine for various chronic pain conditions, including neuropathy. This article examines what LDN is, the pathophysiology of neuropathy with specific examples, the proposed mechanisms by which LDN may alleviate neuropathic symptoms, and evidence from clinical studies and trials. What is Low-Dose Naltrexone? Naltrexone is an opioid receptor antagonist approved for treating alcohol and opioid addiction at standard doses of 50 mg or higher. At these doses, it blocks opioid receptors to prevent euphoria and reduce cravings. Low-dose naltrexone refers to administration at significantly reduced doses—generally 1–5 mg per day, and sometimes even lower. This regimen is used off-label for its potential immunomodulatory and anti-inflammatory effects, particularly in chronic pain and inflammatory conditions. LDN is thought to work through transient opioid receptor blockade, leading to a compensatory increase in endogenous opioid production, and through non-opioid pathways involving glial cell modulation. Because commercial preparations are designed for higher doses, LDN is typically compounded into capsules or liquid formulations. Clinical observations suggest it's well-tolerated, with minimal side effects such as vivid dreams or mild gastrointestinal discomfort—making it an attractive alternative for patients intolerant to standard therapies. What is Neuropathy? Neuropathy, or peripheral neuropathy, encompasses a diverse group of disorders involving damage to peripheral nerves, resulting in sensory, motor, or autonomic dysfunction. Symptoms include pain, numbness, tingling, weakness, and autonomic disturbances. The condition arises from many causes: metabolic (diabetes), toxic (chemotherapy), infectious (herpes zoster), traumatic, autoimmune, nutritional deficiencies (particularly B vitamins), and sometimes idiopathic. Neuropathic pain is often described as burning, stabbing, or electric-shock-like and is mediated by central and peripheral sensitization. Glial cell activation in the central nervous system contributes to neuroinflammation, amplifying pain signals through proinflammatory cytokine release. This chronicity distinguishes neuropathic pain from nociceptive pain and makes it notoriously difficult to treat with conventional analgesics. Common Types of Neuropathy Neuropathies are classified by distribution (e.g., distal symmetric polyneuropathy) or underlying cause. Common examples include: Diabetic peripheral neuropathy  is the most prevalent form, affecting up to 50% of individuals with diabetes. It primarily involves sensory nerves in a stocking-glove distribution, leading to painful symptoms and increased risk of foot ulceration. Chemotherapy-induced peripheral neuropathy  results from neurotoxic agents used in cancer therapy, causing sensory loss, burning pain, numbness, and tingling that may persist long after treatment ends. Trigeminal neuralgia  is a cranial neuropathy involving the fifth cranial nerve, characterized by paroxysmal, lancinating facial pain triggered by innocuous stimuli like light touch or chewing. It often stems from vascular compression or demyelination and can be severely debilitating. Post-herpetic neuralgia  is a complication of herpes zoster (shingles), occurring in 10–20% of cases. Persistent pain follows rash resolution due to viral damage to sensory nerves. Other forms include small-fiber neuropathy (affecting autonomic and pain fibers) and complex regional pain syndrome (CRPS), which involves neuroinflammation and central sensitization. How LDN May Help Neuropathic Pain The analgesic effects of LDN in neuropathy are attributed primarily to its antagonism of Toll-like receptor 4 (TLR4) on microglial cells. Microglia, the resident immune cells of the central nervous system, become activated in response to nerve injury. Once activated, they release proinflammatory cytokines (TNF-α, IL-1β) that exacerbate central sensitization and worsen neuropathic pain. LDN inhibits TLR4 signaling, preventing excessive glial activation and attenuating this inflammatory cascade. This reduces neuroinflammation without fully blocking opioid receptors, allowing endogenous opioids to continue exerting their natural pain-modulating effects. Additionally, the transient opioid receptor blockade may upregulate endorphin production, enhancing the body's own pain control mechanisms. Preclinical evidence supports TLR4-mediated reversal of allodynia in neuropathic models, while clinical observations link LDN's benefits to reduced glial-driven inflammation in conditions like diabetic neuropathy and CRPS. Evidence from Studies and Clinical Trials Research on LDN for neuropathy is growing, though still dominated by small-scale studies, case series, and retrospective reviews. Key findings include: A randomized, double-blind, crossover trial involving 67 patients with painful diabetic neuropathy compared LDN (2–4 mg) to amitriptyline (10–50 mg). LDN demonstrated comparable pain reduction on visual analog scales with a superior safety profile and fewer adverse events. Retrospective cohort studies report significant pain relief in various neuropathic conditions. One analysis of chronic pain patients found LDN effective across multiple pain states, with greater benefits in neuropathic versus nociceptive pain—consistent with the TLR4 antagonism mechanism. Another case series noted improved outcomes in CRPS and diabetic neuropathy. For trigeminal neuralgia, preclinical rat models showed LDN reversing facial allodynia via TLR4 modulation. A retrospective case series in posttraumatic trigeminal neuropathic pain reported LDN as safe and effective. Post-herpetic neuralgia and related conditions (including neuropathic corneal pain) have shown symptom improvement in observational data, with LDN reducing pain and enhancing quality of life. Ongoing or completed trials registered on ClinicalTrials.gov include evaluations for painful diabetic neuropathy (NCT04678895) and CRPS (NCT06306157). The LDN Research Trust has compiled additional clinical and anecdotal reports of benefit in idiopathic, autonomic, and small-fiber neuropathies. Overall, evidence suggests LDN provides moderate pain relief in neuropathies—particularly those with inflammatory components—with low risk. However, larger randomized controlled trials are needed to establish efficacy more definitively. LDN Prescription and Administration LDN is most effectively prescribed by healthcare providers with training in integrative or functional medicine approaches. The process begins with a thorough assessment of the patient's medical history, current symptoms, and treatment goals to ensure LDN is appropriate. Most patients start at carefully titrated doses between 0.1 and 4.5 mg per day, typically administered at bedtime to minimize potential side effects like vivid dreams. Because standard commercial formulations aren't available at these low doses, LDN must be prepared by compounding pharmacies. Regular follow-up appointments are essential for assessing response and making dosage adjustments. This personalized approach—fundamental to integrative and functional medicine practice—helps optimize outcomes for patients managing chronic pain and autoimmune conditions. Comparison to Conventional Treatments Low-dose naltrexone represents a different approach compared to conventional therapies for chronic pain. While traditional treatments—opioids, anticonvulsants, and immunosuppressive medications—typically focus on symptom suppression and carry substantial side effect profiles, LDN works through immune modulation and inflammatory pathway regulation. This mechanism addresses underlying pathophysiology rather than merely masking symptoms. LDN's favorable safety profile, combined with its anti-inflammatory properties, makes it a compelling option for patients seeking alternatives to conventional pharmaceutical interventions. What distinguishes LDN in functional medicine practice is its ability to integrate into comprehensive treatment protocols that may also incorporate physical therapy, nutritional interventions, and other complementary modalities. Patient Experiences Clinical observations and published case series document that many patients with chronic pain and autoimmune conditions respond well to LDN as part of comprehensive care. Patients with diabetic neuropathy often report reduced pain intensity and improved sensory function. Those with multiple sclerosis have shown improvements in disability scores and reduced fatigue. Patients managing inflammatory bowel disease have demonstrated improvements in inflammatory markers and symptom severity. Responses to LDN vary considerably between individuals, and not all patients achieve optimal outcomes. However, clinical experience indicates that LDN protocols provide a reasonable therapeutic option for patients when conventional treatments have shown limited efficacy or tolerability. Future Directions Future studies are needed to determine optimal dosing strategies, ideal treatment durations, and which patient populations are most likely to benefit from LDN therapy. There's growing interest in exploring how LDN might work synergistically with other interventions—nutritional therapies, mind-body practices, and lifestyle modifications—to enhance outcomes. Research into the molecular mechanisms behind LDN's anti-inflammatory and immunomodulatory effects could inform development of new treatments for chronic pain and autoimmune diseases. Expanding clinical trials to include pediatric populations and patients with multiple complex conditions will also be important for understanding LDN's safety and efficacy across diverse groups. As the evidence base grows, low-dose naltrexone may become an increasingly valuable tool in managing chronic and complex conditions. Conclusion Low-dose naltrexone offers a non-opioid approach to managing neuropathy by targeting glial-mediated neuroinflammation through TLR4 inhibition. Preliminary evidence supports its use in diabetic neuropathy, trigeminal neuralgia, and post-herpetic neuralgia, with favorable tolerability. Its integration into functional and integrative medicine frameworks highlights its potential as an adjunctive therapy. While promising, LDN should be used under appropriate medical supervision, and more robust trial data will help clarify its role in neuropathy management. LDN Primer Request Check out the link below to request your free copy of the LDN Primer 2025! Meet Dr. Kim an expert in LDN, Integrative & Functional Medicine At Direct Integrative Care, Dr. Kim is dedicated to guiding you on your path to wellness through a deeply personalized and supportive approach. We focus on integrative medicine, looking beyond symptoms to uncover the root causes of chronic conditions and develop a treatment plan tailored specifically to your unique health journey. By combining compassionate care with innovative therapies, our goal is to empower you with the knowledge and tools needed to achieve lasting health. We invite you to explore our website to learn more about how our patient-centered practice can help you find balance and vitality.  Yoon Hang Kim MD Integrative & Functional Medicine Physician Virtual Practice Serving IA, IL, MO, FL, GA, and TX www.directintegrativecare.com References Chopra, P., & Cooper, M. S. (2013). Treatment of complex regional pain syndrome (CRPS) using low dose naltrexone (LDN). Journal of Neuroimmune Pharmacology, 8 (3), 470–476. https://doi.org/10.1007/s11481-013-9451-y Hutchinson, M. R., Zhang, Y., Brown, K., Coats, B. D., Shridhar, M., Sholar, P. W., Patel, S. J., Crysdale, N. Y., Harrison, J. A., Maier, S. F., Rice, K. C., & Watkins, L. R. (2008). Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: Involvement of toll-like receptor 4 (TLR4). European Journal of Neuroscience, 28 (1), 20–29. https://doi.org/10.1111/j.1460-9568.2008.06321.x Kim, P. S., & Fishman, M. A. (2020). Low-dose naltrexone for chronic pain: Update and systemic review. Current Pain and Headache Reports, 24 (10), 64. https://doi.org/10.1007/s11916-020-00898-0 Martin, S. J., McAnally, H. B., Okediji, P., & Rogosnitzky, M. (2022). Low-dose naltrexone, an opioid-receptor antagonist, is a broad-spectrum analgesic: A retrospective cohort study. Pain Management, 12 (6), 699–709. https://doi.org/10.2217/pmt-2021-0122 Patten, D. K., Schultz, B. G., & Berlau, D. J. (2018). The safety and efficacy of low-dose naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, Crohn's disease, and other chronic pain disorders. Pharmacotherapy, 38 (3), 382–389. https://doi.org/10.1002/phar.2086 Soin, A., Soin, Y., Dann, T., Buenaventura, R., Ferguson, J., Atluri, S., & Sachdeva, H. (2021). Low-dose naltrexone use for patients with chronic regional pain syndrome: A systematic literature review. Pain Physician, 24 (4), E393–E406. Srinivasan, A., Dutta, P., Bansal, D., Chakrabarti, A., Bhansali, A. K., & Hota, D. (2021). Efficacy and safety of low-dose naltrexone in painful diabetic neuropathy: A randomized, double-blind, active-control, crossover clinical trial. Journal of Diabetes, 13 (10), 770–778. https://doi.org/10.1111/1753-0407.13202 Younger, J., Mackey, S. (2009). Fibromyalgia symptoms are reduced by low-dose naltrexone: A pilot study. Pain Medicine, 10 (4), 663–672. https://doi.org/10.1111/j.1526-4637.2009.00613.x Younger, J., Noor, N., McCue, R., & Mackey, S. (2013). Low-dose naltrexone for the treatment of fibromyalgia: Findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis & Rheumatism, 65 (2), 529–538. https://doi.org/10.1002/art.37734 Younger, J., Parkitny, L., & McLain, D. (2014). The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clinical Rheumatology, 33 (4), 451–459. https://doi.org/10.1007/s10067-014-2517-2

Integrative Functional Medicine Approach to Enhancing Blood Flow Healthy blood flow is a foundation of systemic wellness. For practitioners of integrative medicine  and functional medicine , addressing poor circulation isn’t just about managing symptoms—it is about optimizing the body’s fundamental delivery system. When blood flow  is compromised, nutrient delivery and waste removal suffer, impacting everything from energy levels to tissue repair. Optimizing blood flow through integrative and functional medicine approaches offers significant health benefits, including improved cardiovascular function, enhanced oxygen delivery, and better overall wellness. This guide explores how these holistic disciplines approach vascular health, specifically examining the critical role of nitric oxide pathways and evidence-based supplementation. Maintaining optimal NO levels is essential for healthy circulation and cardiovascular health, as nitric oxide is a natural vasodilator that supports blood flow. Nitric oxide matters because it acts as a vital signaling molecule, promoting systemic wellness by improving circulation and oxygen delivery throughout the body. Introduction to Cardiovascular Health Cardiovascular pathophysiology represents the fundamental cornerstone of comprehensive systemic wellness optimization, exerting profound influence across multiple physiological parameters including metabolic energy production and overall longevity outcomes. Central to this complex cardiovascular system is nitric oxide, a critical endogenous signaling molecule with established vasodilatory properties that facilitates optimal hemodynamic function and maintains endothelial integrity. Evidence-based research demonstrates that nitric oxide biosynthesis is essential for maintaining normotensive blood pressure parameters, as this molecular mediator promotes vascular smooth muscle relaxation and arterial vasodilation, thereby optimizing systemic circulation and peripheral perfusion throughout the cardiovascular network. When nitric oxide production maintains appropriate physiological levels through established biochemical pathways, the incidence of cardiovascular disease significantly decreases, and comprehensive cardiovascular health outcomes demonstrate measurable improvement. Through evidence-based understanding and targeted support of nitric oxide-dependent signaling pathways, healthcare practitioners and patients can implement proactive, integrative interventions to optimize cardiac function and ensure sustained hemodynamic circulation for long-term cardiovascular wellness. Understanding Blood Flow Blood flow represents the fundamental circulatory mechanism upon which optimal physiological function depends, serving as the critical transport system that delivers essential oxygen and nutrients to cellular structures throughout the human body, much like the evidence-based complementary and alternative therapies that Dr. Kim incorporates into comprehensive medical treatments. This sophisticated vascular process relies extensively on the capacity of blood vessels to demonstrate dynamic expansion and contraction responses, a regulatory function predominantly governed by nitric oxide, which functions as a naturally occurring vasodilator with demonstrated efficacy in clinical applications. As a potent endogenous compound with vasodilatory properties, nitric oxide acts through established biochemical pathways to facilitate vessel dilation, thereby promoting enhanced blood flow dynamics and ensuring efficient oxygen delivery to target tissues and organ systems, particularly beneficial for patients with cardiovascular conditions, autoimmune disorders, and chronic conditions such as fibromyalgia and neuropathy. Maintaining optimal blood flow patterns proves essential for comprehensive cardiovascular health management, as this physiological process helps stabilize blood pressure parameters and significantly reduces the risk of developing cardiovascular disease and related complications commonly addressed through integrative medicine approaches. Supporting endogenous nitric oxide production through evidence-based interventions remains a cornerstone therapeutic strategy for preserving optimal blood vessel function and ensuring that the body's circulatory system operates at peak efficiency, utilizing the same holistic principles found in functional medicine practices that address root causes of disease through comprehensive assessment and targeted interventions. The Functional Medicine Approach to Blood Flow Unlike conventional models that may focus primarily on treating established vascular disease, a functional medicine perspective  seeks to identify the root causes of circulatory inefficiency before pathology sets in, emphasizing a holistic, root-cause approach to cardiovascular health. In this paradigm, blood flow  is viewed as a dynamic marker of overall vitality. Functional medicine practitioners often assess vascular health by looking at endothelial function—the health of the inner lining of blood vessels. When the endothelium is damaged or sluggish, it fails to produce adequate signaling molecules required for vasodilation (the widening of blood vessels). Optimizing circulation involves a comprehensive strategy: Nutrient Status:  Ensuring the body has the raw materials for vascular repair. Inflammation Control:  Reducing systemic inflammation that damages vessel walls. Lifestyle Factors:  Incorporating movement and stress reduction to support hemodynamic balance. Functional medicine solutions address these root causes by personalizing interventions that restore natural balance, focusing on diet, lifestyle, and correcting systemic imbalances for optimal circulatory health. Integrative Medicine and the Nitric Oxide Pathway A core component of vascular health in integrative medicine  is the management of nitric oxide (NO). Nitric oxide plays a crucial role in cardiovascular health and circulation, acting as a biological signaling molecule essential for vasodilation. Note that while often confused in casual conversation with nitrous oxide  (an anesthetic gas), we are specifically focusing on nitric oxide . However, understanding the distinction is vital for patients. Nitrous oxide  is used in dental sedation and pain management, whereas nitric oxide is produced naturally by the body to relax vascular smooth muscles. Nitric oxide widens blood vessels, enhancing blood flow and oxygen delivery, which is crucial for overall cardiovascular health. Enhancing the bioavailability of nitric oxide is a primary goal when attempting to improve blood flow  naturally. Mechanisms of Action The endothelium produces nitric oxide to signal blood vessels to relax. This reduces vascular resistance and improves circulation to extremities and vital organs. Integrative medicine  protocols often utilize specific precursors to fuel this pathway: L-Arginine and L-Citrulline:  These amino acids serve as direct substrates for NO synthesis. L-arginine is an amino acid that acts as a precursor for nitric oxide, while L-citrulline is a non-essential amino acid that is naturally synthesized in the body and can be converted into L-arginine. Dietary Nitrates:  Compounds found in foods like beetroot are converted via the nitrate-nitrite-NO pathway, offering an alternative route for vasodilation that is particularly useful if the endothelial pathway is compromised. Nitric oxide synthase is the key enzyme responsible for converting these amino acids into nitric oxide, playing a central role in regulating blood flow and vascular health. Key Supplements for Circulatory Support When selecting interventions, evidence supports several natural compounds that align with functional medicine  principles. Dietary supplements are commonly used in functional medicine to support circulatory health. These supplements aim to restore physiological balance and enhance endothelial performance, with many focusing on the benefits of nitric oxide for cardiovascular and circulatory health, such as improved blood flow, heart function, and overall wellness. 1. Beetroot Extract and Nitrates Beetroot is a powerhouse for vascular health and is considered one of the most effective nitric oxide supplements. Rich in inorganic nitrates, it bypasses the enzymatic pathways that are often dysfunctional in aging adults. Mechanism:  Converts to nitric oxide in the mouth and stomach. Evidence:  Systematic reviews suggest consistent improvements in blood pressure and endothelial function, and show that beetroot extract reduces high blood pressure through its effects on nitric oxide production. Clinical Note:  Effective doses typically provide at least 370 mg of nitrates. 2. L-Citrulline vs. L-Arginine While L-arginine is the direct precursor, L-citrulline is often preferred in integrative medicine  protocols due to better absorption. L-citrulline is converted into L-arginine in the kidneys, sustaining plasma levels of arginine longer than direct arginine supplementation. Both L-citrulline and L-arginine support cardiovascular health by promoting vasodilation, which enhances blood flow and helps reduce strain on the heart. Dosing:  Studies suggest 5.6–8 g of L-citrulline for optimal vasodilation. These supplements also help maintain healthy blood pressure levels within the normal range. 3. Omega-3 Fatty Acids Beyond their anti-inflammatory properties, Omega-3s—commonly found in fish oil, a primary source of EPA and DHA—support the structural integrity of blood vessels. In addition to reducing systemic inflammation, the antioxidant properties of omega-3 fatty acids help prevent the endothelial damage that restricts blood flow . 4. Aged Garlic Extract Garlic compounds, specifically allicin-rich preparations, have been shown to promote vasodilation and improve arterial stiffness, making them a staple in cardiovascular support strategies. Aged garlic extract, in particular, supports vascular function by enhancing the health and flexibility of blood vessels. Additionally, aged garlic extract contributes to metabolic health, supporting balanced blood sugar and overall wellness. Lifestyle Factors Affecting Health Evidence-based lifestyle interventions demonstrate profound therapeutic efficacy in optimizing cardiovascular health and enhancing endothelial nitric oxide synthesis through comprehensive integrative approaches. A scientifically-formulated nutritional protocol—particularly one incorporating antioxidant-rich phytonutrient sources including cruciferous vegetables, polyphenol-abundant fruits, and complex carbohydrate whole grain substrates—provides essential cofactors and precursors for nitric oxide biosynthesis while supporting optimal endothelial function and hemodynamic parameters. Structured physical activity protocols not only strengthen myocardial contractility but also demonstrate clinically significant reductions in systolic and diastolic blood pressure measurements while upregulating nitric oxide bioavailability through enhanced endothelial nitric oxide synthase activity. Implementation of evidence-based mind-body therapeutic modalities, including diaphragmatic breathing techniques and mindfulness-based stress reduction protocols, can significantly attenuate oxidative stress markers and support optimal cardiovascular function through parasympathetic nervous system activation. Through systematic implementation of these evidence-based integrative lifestyle modifications, patients can achieve measurable improvements in nitric oxide production, enhance endothelial-dependent vasodilation, and demonstrate clinically significant risk reduction in cardiovascular disease endpoints. The Effects of Chronic Stress Chronic stress represents a clinically significant yet frequently underrecognized pathophysiological factor in cardiovascular health management, according to evidence-based integrative medicine approaches. The persistent activation of stress-response mechanisms triggers the body's sympathetic nervous system, resulting in vasoconstriction and elevated blood pressure parameters through well-documented neurohormonal pathways. Over time, these sustained physiological responses lead to endothelial dysfunction, characterized by decreased nitric oxide bioavailability and compromised vascular endothelium function, as demonstrated through comprehensive functional medicine assessments. The clinical manifestation includes substantially increased cardiovascular disease risk profiles and compromised circulatory system integrity across multiple patient populations. Evidence-based stress management interventions, including mind-body techniques such as deep breathing protocols, meditation practices, and therapeutic yoga modalities—approaches widely incorporated in integrative and holistic medicine—have been clinically validated to restore optimal nitric oxide production, support healthy vascular function, and provide comprehensive cardiovascular protection. Through the implementation of integrative approaches to chronic stress management, patients can achieve significant therapeutic outcomes in maintaining healthy blood pressure parameters and substantially reducing cardiovascular disease risk factors, representing a fundamental component of preventive and functional medicine practice. Safety and Clinical Considerations In the spirit of integrative medicine , safety is paramount. Supplements are powerful tools, but they must be used methodically. Individuals with kidney disease should consult a healthcare provider before using supplements that affect blood flow. People with high blood pressure should also exercise caution when considering these supplements. Interaction Risks Patients taking anti-hypertensives or blood thinners must exercise caution. Enhancing blood flow  naturally can potentiate the effects of these medications, leading to hypotension (low blood pressure) or increased bleeding risk. Some supplements used to enhance blood flow are also commonly used to address erectile dysfunction and support sexual function. Quality Assurance The supplement industry is not strictly regulated. Functional medicine  practitioners emphasize using "pharmaceutical grade" or third-party tested products to ensure purity and potency. Professional Guidance Before starting any regimen, consultation with a healthcare provider is essential. This ensures that the chosen therapy aligns with the patient's unique physiological profile and current medication list. Conclusion Optimizing blood flow  through integrative medicine  and functional medicine  offers a proactive approach to cardiovascular health. Preventive medicine plays a crucial role in maintaining cardiovascular and overall health by emphasizing early intervention and lifestyle modifications. By focusing on the nitric oxide pathways and utilizing high-quality, evidence-based supplements like beetroot extract and L-citrulline, patients can support their circulatory systems naturally. Optimizing blood flow and nitric oxide production also supports immune function and gut health, contributing to broader systemic wellness. As with all medical interventions, a personalized, methodical approach yields the best results. Always consult with a qualified physician to integrate these strategies safely into your healthcare routine. About Dr. Kim Dr. Yoon Hang "John" Kim, residential fellowship trained in integrative medicine at University of Arizona and a recipient of the 2024 Functional Medicine for All scholarship from the Institute for Functional Medicine, brings over 20 years of experience in integrative and functional medicine to his telemedicine practice. After serving as chief wellness officer at a community hospital in Carthage, IL, where he provided care to rural and underserved populations, Dr. Kim now offers virtual integrative and functional medicine services, making personalized, evidence-based care accessible to patients regardless of location. His approach combines functional medicine lab testing with complementary therapies such as meditation, yoga, tai chi, and lifestyle interventions using food and physical activity as medicine, addressing the root causes of disease. Dr. Kim earned his medical degree from the Medical College of Wisconsin, completed a master’s in public health at San Diego State University, and trained with Dr. Andrew Weil during his residential fellowship at the University of Arizona. Certified by the American Board of Preventive Medicine, the American Board of Medical Acupuncture, and the American Board of Integrative and Holistic Medicine, he has also contributed to the field as a faculty member, consultant, and founder of the Integrative Health Studies Certificate program at the University of West Georgia. With clinical interests in autoimmune conditions, chronic pain, integrative oncology, and gastrointestinal disorders, Dr. Kim specializes in treating complex conditions such as fibromyalgia, chronic fatigue syndrome, long COVID symptoms, and toxic mold illness, and has authored two books and over 20 articles while helping establish integrative medicine practices across various institutions. Professional Inquiries:   www.yoonhangkim.com Clinical Inquiries:   www.directintegrativecare.com https://youtu.be/qNxc1mc9yA8?si=RUUs8EJZShr9P7_D Meet Dr. Kim Integrative & Functional Medicine and LDN Expert References Bahra, M., & Kapil, V. (2022). Dietary supplements for improving nitric-oxide synthesis. Medicine , 2(1), 1–12. Lidder, S., & Webb, A. J. (2013). Vascular effects of dietary nitrate via the nitrate-nitrite-nitric oxide pathway. British Journal of Clinical Pharmacology , 75(3), 677–696. Mahdi, A., & Collins, P. (2023). Dietary arginine and citrulline supplements for cardiovascular health and athletic performance. Nutrients , 15(5), 1268. Mayo Clinic. (2024). L-arginine: Does it lower blood pressure? Verywell Health. (2025). Dietary supplements for blood flow.

Edited by Yoon Hang Kim, MD, MPH Dr. Yoon Hang "John" Kim, a recipient of the 2024 Functional Medicine for All scholarship from the Institute for Functional Medicine, brings over 20 years of experience in integrative and functional medicine to his telemedicine practice. After serving as chief wellness officer at a community hospital in Carthage, IL, where he provided care to rural and underserved populations, Dr. Kim now offers virtual integrative and functional medicine services, making personalized, evidence-based care accessible to patients regardless of location. His approach combines functional medicine lab testing with complementary therapies, including meditation, yoga, tai chi, and lifestyle interventions using food and physical activity as medicine, addressing the root causes of disease. Dr. Kim earned his medical degree from the Medical College of Wisconsin, completed a master’s in public health at San Diego State University, and trained with Dr. Andrew Weil during his residential fellowship at the University of Arizona. Certified by the American Board of Preventive Medicine, the American Board of Medical Acupuncture, and the American Board of Integrative and Holistic Medicine, he has contributed as a faculty member, consultant, and founder of the Integrative Health Studies Certificate program at the University of West Georgia. Dr. Kim specializes in autoimmune conditions, chronic pain, integrative oncology, and gastrointestinal disorders, treating complex conditions such as fibromyalgia, chronic fatigue syndrome, long COVID, and toxic mold illness. He has authored two books and over 20 articles while helping establish integrative medicine practices across various institutions. Professional Inquiries:   www.yoonhangkim.com Clinical Inquiries:   www.directintegrativecare.com Boron and Prostate Cancer: An Introduction - Boron Prostate Health Integrative Functional Medicine Boron is a trace mineral found in fruits, vegetables, nuts, and legumes. While not officially classified as essential for humans, some researchers consider it vital due to its roles in cellular function and metabolism. Boron has been studied for hormone regulation, bone health, and inflammation modulation. Recent research has explored its potential impact on prostate health, particularly prostate cancer risk. Epidemiological, in vitro, and animal studies suggest possible protective effects, although human evidence remains mixed. Many epidemiological studies account for confounding factors such as alcohol consumption, body mass index, and dietary caloric intake. Boron-containing compounds are increasingly investigated as preventive and therapeutic agents in cancer research. This review summarizes the current evidence from epidemiology, preclinical studies, clinical observations, and expert opinion. Epidemiological Evidence of Prostate Cancer Risk Studies Supporting Protective Effects Several observational studies have examined dietary boron and prostate cancer risk. Data from the Third National Health and Nutrition Examination Survey (NHANES III) showed that higher dietary boron intake was associated with a lower risk of prostate cancer in a dose-dependent manner. Men in the highest quartile of boron intake had an adjusted odds ratio of 0.46 (95% CI: 0.21–0.98) compared to the lowest quartile (Cui et al., 2004). Risk was 52% lower in men consuming >1.8 mg/day of boron compared to ≤0.9 mg/day. No correlation was observed when intake was <1.17 mg/day (Pizzorno, 2015). An ecological study in Texas reported that higher groundwater boron levels correlated with lower prostate cancer incidence and mortality (R = 0.6 for both), while selenium showed no correlation (R = 0.1–0.2) (Barranco et al., 2007). Conflicting Evidence However, the VITamins And Lifestyle (VITAL) cohort study of 35,244 men found no association between dietary or total boron intake and prostate cancer risk (hazard ratio 1.17; 95% CI: 0.85–1.61) (Gonzalez et al., 2007). Foods high in boron were not associated with decreased risk. These discrepancies may result from differences in study design, sample size, dietary assessment, and population characteristics. Variations in controlling for confounders like alcohol intake, BMI, and total caloric intake may also contribute. Preclinical Evidence In Vitro Studies Boric acid, the main plasma form of boron, inhibits proliferation of prostate cancer cell lines (DU-145, LNCaP) in a dose-dependent manner, while requiring higher concentrations to affect non-tumor cells (Barranco & Eckhert, 2004). Recent studies (2025) on boron derivatives such as sodium pentaborate pentahydrate (SPP) and sodium perborate tetrahydrate (SPT) show selective cytotoxicity toward prostate cancer cells, targeting mitochondrial function and RNA metabolism, with effects varying by androgen status (Demirdogen et al., 2025). Proposed mechanisms include: Inhibition of prostate-specific antigen (PSA) activity via boronic acid Reduction in intracellular calcium signaling Induction of stress granule formation Modulation of inflammatory pathways Downregulation of IGF-1 signaling Impairment of lipid metabolism through mitochondrial regulators (ACSL3, PYCR1, PYCR2) Induction of apoptosis in prostate cancer cells Animal Studies Dietary boron supplementation in mice reduced LNCaP tumor growth by 25–38% and decreased serum PSA by 86–89% (Gallardo-Williams et al., 2004). Hollow boron nitride spheres suppressed tumor growth and enhanced paclitaxel efficacy in mouse models (Li et al., 2017). Hexagonal boron nitride nanoparticles promoted apoptosis and reduced metastatic potential (Emanet et al., 2019). Mechanisms of Boron’s Effects Boron affects prostate cancer cells via multiple pathways: Proliferation inhibition:  Reduces tumor cell growth in both androgen-sensitive and independent cell lines. Apoptosis induction:  Triggers programmed cell death selectively in malignant cells. Migration reduction:  Disrupts cellular architecture, limiting metastatic spread. Hormonal modulation:  Influences testosterone metabolism, potentially complementing androgen deprivation therapy. Bone health support:  May prevent metastatic growth in bone tissue. Research relies on rigorous in vitro, animal, and dietary studies to clarify boron’s role in prostate cancer risk and progression. Clinical Trial Evidence No registered human clinical trials have specifically evaluated boron for prostate cancer prevention or treatment (NIH ODS, 2024). Related human studies include: Inflammation:  10 mg/day boron supplementation for 1 week reduced TNF-α by 20%, hs-CRP by ~50%, and IL-6 (Naghii et al., 2011). Prostate size:  Men consuming ~6 mg/day had smaller prostates than those consuming 0.64–0.88 mg/day, with no significant PSA differences (NIH ODS, 2024). Hormones:  Boron supplementation increased free testosterone in men and supported bone health in postmenopausal women (Naghii et al., 2011). Boron Neutron Capture Therapy (BNCT):  Preclinical prostate studies show promise; PSMA-targeted boron agents are under development (Takahara et al., 2015; Wilson et al., 2019). Expert Opinion and Clinical Perspectives Lara Pizzorno (2015) recommends considering 3 mg/day boron supplementation for individuals with low fruit and vegetable intake or at risk of osteopenia, osteoporosis, osteoarthritis, or hormone-sensitive cancers. Some integrative practitioners report PSA reduction and prostate size improvement with higher doses (3–20 mg/day), though systematic documentation is lacking. Patient Experience No formal patient-reported outcome studies exist. Anecdotal reports suggest subjective improvements in urinary symptoms and PSA levels, but these are not systematically documented. Dietary Boron Intake: Sources and Recommendations Boron is obtained primarily from plant-based foods. Typical intake ranges from 1–3 mg/day; the tolerable upper intake is 20 mg/day. Key sources: Fruits:  Apples, pears, grapes, avocados, prunes, raisins Vegetables:  Broccoli, carrots, leafy greens Nuts/Legumes:  Almonds, peanuts, hazelnuts, lentils Other:  Wine, coffee, milk Supplementation may be considered for intakes <3 mg/day, especially in individuals with low fruit and vegetable consumption (Pizzorno, 2015). Summary of Evidence Evidence Type Availability Quality Key Findings Epidemiological Mixed Moderate Conflicting results In Vitro Strong Good Dose-dependent inhibition of cancer cells Animal Strong Good 25–38% tumor reduction, 86–89% PSA reduction Human RCTs None N/A Evidence gap Expert Opinion Cautiously Favorable Low-Moderate Supports 3 mg/day for at-risk individuals Patient Experience Anecdotal Very Low No systematic data Conclusions - Boron Prostate Health Integrative Functional Medicine Preclinical studies suggest boron may inhibit prostate cancer growth and reduce tumor progression. Epidemiological data indicate higher boron exposure may correlate with lower prostate cancer risk. The major limitation is the absence of human clinical trials specifically targeting prostate cancer, highlighting a critical evidence gap. Boron appears safe up to 20 mg/day, but supplementation for prostate health should be approached cautiously. Boron Prostate Health Integrative Functional Medicine - At this time, I would recommend taking Boron up to 3 mg/day. Clinical considerations: 3 mg/day appears safe with potential anti-inflammatory benefits Upper limit of 20 mg/day is low-risk Dietary intake from fruits and vegetables is preferred Human clinical trials are needed to establish efficacy At Direct Integrative Care, Dr. Kim is dedicated to guiding you on your path to wellness through a deeply personalized and supportive approach. We focus on integrative medicine, looking beyond symptoms to uncover the root causes of chronic conditions and develop a treatment plan tailored specifically to your unique health journey. By combining compassionate care with innovative therapies, our goal is to empower you with the knowledge and tools needed to achieve lasting health. We invite you to explore our website to learn more about how our patient-centered practice can help you find balance and vitality.  Yoon Hang Kim MD Integrative & Functional Medicine Physician Virtual Practice Serving IA, IL, MO, FL, GA, and TX www.directintegrativecare.com References Barranco, W. T., & Eckhert, C. D. (2004). Boric acid inhibits human prostate cancer cell proliferation. Cancer Letters , 216(1), 21–29. https://doi.org/10.1016/j.canlet.2004.06.001 Barranco, W. T., Hudak, P. F., & Eckhert, C. D. (2007). Evaluation of ecological and in vitro effects of boron on prostate cancer risk (United States). Cancer Causes & Control , 18(1), 71–77. https://doi.org/10.1007/s10552-006-0077-8 Cui, Y., et al. (2004). Dietary boron intake and prostate cancer risk. Oncology Reports , 11(4), 887–892. https://doi.org/10.3892/or.11.4.887 Demirdogen, R. E., et al. (2025). Proteomic insights into the anti-cancer mechanisms of boron-based compounds in prostate cancer. Journal of Proteomics . [Epub ahead of print] Emanet, M., et al. (2019). Hexagonal Boron Nitride Nanoparticles for Prostate Cancer Treatment. ACS Applied Nano Materials , 2(12), 7493–7504. Gallardo-Williams, M. T., et al. (2004). Boron supplementation inhibits the growth and local expression of IGF-1 in human prostate adenocarcinoma (LNCaP) tumors in nude mice. Toxicologic Pathology , 32(1), 73–78. https://doi.org/10.1080/01926230490260899 Gonzalez, A., et al. (2007). Boron intake and prostate cancer risk. Cancer Causes & Control , 18(10), 1131–1140. https://doi.org/10.1007/s10552-007-9052-2 Li, X., et al. (2017). Hollow boron nitride nanospheres as boron reservoir for prostate cancer treatment. Nature Communications , 8, 13936. https://doi.org/10.1038/ncomms13936 Naghii, M. R., et al. (2011). Comparative effects of daily and weekly boron supplementation on plasma steroid hormones and proinflammatory cytokines. Journal of Trace Elements in Medicine and Biology , 25(1), 54–58. Pizzorno, L. (2015). Nothing boring about boron. Integrative Medicine: A Clinician's Journal , 14(4), 35–48. Scorei, R. I., & Popa, R. (2013). Sugar-borate esters—potential chemical agents in prostate cancer chemoprevention. Anti-Cancer Agents in Medicinal Chemistry , 13(6), 901–909. Takahara, K., et al. (2015). The anti-proliferative effect of boron neutron capture therapy in a prostate cancer xenograft model. PLoS ONE , 10(9), e0136981. https://doi.org/10.1371/journal.pone.0136981 U.S. Department of Health and Human Services, NIH Office of Dietary Supplements. (2024). Boron: Fact sheet for health professionals. https://ods.od.nih.gov/factsheets/Boron-HealthProfessional/ Wilson, J. J., et al. (2019). Synthesis and initial biological evaluation of boron-containing PSMA ligands for treatment of prostate cancer using BNCT. Molecular Pharmaceutics , 16(9), 3831–3841. https://doi.org/10.1021/acs.molpharmaceut.9b00464

Edited By Yoon Hang Kim MD MPH About Dr. Kim Dr. Yoon Hang "John" Kim, a recipient of the 2024 Functional Medicine for All scholarship from the Institute for Functional Medicine, brings over 20 years of experience in integrative and functional medicine to his telemedicine practice. After serving as chief wellness officer at a community hospital in Carthage, IL, where he provided care to rural and underserved populations, Dr. Kim now offers virtual integrative and functional medicine services, making personalized, evidence-based care accessible to patients regardless of location. His approach combines functional medicine lab testing with complementary therapies such as meditation, yoga, tai chi, and lifestyle interventions using food and physical activity as medicine, addressing the root causes of disease. Dr. Kim earned his medical degree from the Medical College of Wisconsin, completed a master’s in public health at San Diego State University, and trained with Dr. Andrew Weil during his residential fellowship at the University of Arizona. Certified by the American Board of Preventive Medicine, the American Board of Medical Acupuncture, and the American Board of Integrative and Holistic Medicine, he has also contributed to the field as a faculty member, consultant, and founder of the Integrative Health Studies Certificate program at the University of West Georgia. With clinical interests in autoimmune conditions, chronic pain, integrative oncology, and gastrointestinal disorders, Dr. Kim specializes in treating complex conditions such as fibromyalgia, chronic fatigue syndrome, long COVID symptoms, and toxic mold illness, and has authored two books and over 20 articles while helping establish integrative medicine practices across various institutions. Professional Inquiry: www.yoonhangkim.com Clinical Inquiry: www.directintegrativecare.com Low-Dose Naltrexone for Weight Loss: Mechanisms, Evidence, and Comparison with Naltrexone/Bupropion Combination Therapy Obesity remains a significant public health challenge, contributing to comorbidities such as type 2 diabetes, cardiovascular disease, and metabolic syndrome. Pharmacological interventions, when combined with lifestyle modifications, offer adjunctive support for weight management. Among emerging options, low-dose naltrexone (LDN) , typically dosed at 1–5 mg daily, has garnered interest for its potential off-label use in weight loss due to its immunomodulatory and anti-inflammatory effects. Additionally, the fixed-dose combination of standard-dose naltrexone (32 mg) and bupropion (360 mg), marketed as Contrave, is an FDA-approved therapy specifically for chronic weight management. This article reviews the mechanisms and evidence for LDN in weight loss and examines the established naltrexone/bupropion combination. Low Dose Naltrexone Weight Loss: Mechanisms of Action - LDN Weight Loss Integrative Functional Medicine San Antonio TX Naltrexone is an opioid receptor antagonist primarily approved at higher doses (50 mg) for opioid and alcohol dependence. At high doses, naltrexone blocks opioid receptors, preventing users from experiencing the euphoric feelings associated with opioids and alcohol. At low doses, LDN is hypothesized to transiently block opioid receptors, leading to a rebound increase in endogenous endorphins, which play a role in mood regulation and pain relief, and modulation of glial cell activity. LDN work includes reducing inflammation and supporting mood regulation. This may reduce systemic inflammation, improve insulin sensitivity, regulate appetite, and enhance sleep quality—all factors implicated in obesity. Low dose naltrexone may support appetite control and reduce food cravings by modulating the opioid system, which is involved in addictive eating behaviors. Proposed pathways include decreased insulin resistance, reduced inflammatory cytokines, and indirect effects on growth hormone secretion, potentially preserving lean muscle mass while promoting fat loss. LDN may also help address leptin resistance, which can impair hunger signals and contribute to overeating. How low dose naltrexone is thought to work for weight loss involves its impact on the opioid system and endorphin release, influencing appetite and metabolic pathways. In contrast, the naltrexone and bupropion combination targets central nervous system pathways regulating energy balance and is FDA approved for weight loss. Bupropion, a dopamine and norepinephrine reuptake inhibitor, stimulates pro-opiomelanocortin (POMC) neurons in the hypothalamus, promoting satiety and energy expenditure. Naltrexone at standard doses blocks autoinhibitory feedback on POMC neurons, enhancing these effects synergistically. This combination primarily suppresses appetite and reduces food reward, distinct from LDN’s broader anti-inflammatory focus. Weight loss naltrexone (in combination with bupropion) is supported by clinical evidence. Evidence for Low-Dose Naltrexone in Weight Loss Evidence supporting LDN for weight loss is largely preliminary and derived from observational data, small trials, and mechanistic studies rather than large randomized controlled trials (RCTs). Systematic reviews indicate limited high-quality data specific to obesity, with most research focusing on LDN’s role in autoimmune or inflammatory conditions. Potential benefits include improved insulin regulation and reduced cravings, particularly in conditions like polycystic ovary syndrome or hypothyroidism-associated weight gain, and LDN may also help regulate blood sugar. LDN may help manage binge eating and reduce cravings for certain foods, which can support healthier eating behaviors. While some individuals report weight loss, successful weight loss with LDN still requires maintaining a caloric deficit and consuming fewer calories than expended. It is important to address eating disorders and ensure medical supervision when taking naltrexone for weight loss, as misuse or unsupervised use can be harmful. However, no large-scale RCTs have confirmed significant, sustained weight loss with LDN monotherapy. Clinical use remains off-label, and effects appear modest, often requiring combination with diet and exercise. In clinical practice, taking naltrexone may help some individuals lose weight by reducing cravings and supporting healthier eating patterns. LDN Weight Loss Integrative Functional Medicine San Antonio TX Review of Naltrexone/Bupropion Combination (Contrave) The naltrexone/bupropion extended-release formulation combines two medications that work synergistically: naltrexone helps reduce cravings, while bupropion boosts energy and suppresses appetite. Robust evidence from phase III RCTs, including the COR-I, COR-II, COR-BMOD, and COR-Diabetes trials, involving over 4,500 participants, supports its efficacy. These 56-week studies demonstrated placebo-subtracted weight loss of approximately 4.7% (range 3.2–5.2%), with 26–33% more patients achieving ≥5% weight loss compared to placebo when combined with lifestyle interventions. In intensive behavior modification settings, weight loss exceeded 9%. Improvements in cardiometabolic parameters, such as waist circumference, triglycerides, and insulin sensitivity, were also observed. Long-term data suggest sustained benefits, though nausea is a common adverse effect leading to discontinuation in some patients. It is important to use this combination only under medical supervision to manage potential risks and side effects. Compared to LDN, the standard-dose combination offers more predictable and clinically meaningful weight loss, supported by regulatory approval and larger evidence bases. Naltrexone is also used in the management of substance use disorder, highlighting its established safety profile in clinical use. No direct head-to-head trials exist between LDN and Contrave, but the latter’s targeted central appetite regulation appears superior for primary obesity management. Potential Side Effects of LDN Low dose naltrexone (LDN) represents an evidence-based therapeutic intervention typically prescribed at significantly reduced dosages compared to those utilized in opioid or alcohol dependency treatment protocols, and demonstrates excellent tolerability profiles across diverse patient populations. However, as with any pharmaceutical intervention in integrative medicine practice, comprehensive awareness of potential adverse reactions and implementation under qualified healthcare supervision remains paramount to optimal patient outcomes. The majority of patients receiving low dose naltrexone therapy for weight management, metabolic optimization, or associated endocrine disorders experience only transient, mild adverse effects that align with established clinical research findings. These may encompass cephalgia, gastrointestinal disturbances such as nausea, enhanced dream activity, or minor sleep pattern modifications. Such symptoms characteristically resolve within several weeks as the patient's physiological systems achieve therapeutic adaptation to the prescribed naltrexone dosage. Numerous patients report significant improvements in sleep architecture over time, which provides additional therapeutic support for weight management protocols and comprehensive wellness optimization. In rare clinical instances, more significant adverse reactions may manifest. These include severe dermatological responses, allergic hypersensitivity reactions, chest discomfort, or respiratory compromise. Should any severe symptomatology or dermatological manifestations occur, immediate medical evaluation becomes critically important for patient safety. While such reactions remain infrequently documented in clinical literature, maintaining vigilant patient monitoring ensures optimal safety protocols throughout the treatment continuum. LDN demonstrates potential pharmaceutical interactions, particularly with opioid analgesics, and may present contraindications for individuals with specific medical conditions including hepatic or renal dysfunction. Comprehensive disclosure of complete medical history and concurrent medications or nutraceutical supplements to your healthcare provider before initiating low dose naltrexone therapy remains essential for safe clinical practice. This becomes particularly crucial when utilizing LDN for managing severe manifestations of autoimmune pathologies, chronic pain syndromes, or irritable bowel syndrome, as these complex conditions require sophisticated clinical monitoring and integrative treatment approaches. To optimize therapeutic outcomes while minimizing adverse effects, adherence to evidence-based treatment protocols established by qualified healthcare practitioners becomes fundamental. LDN therapy typically commences at conservative dosages, generally ranging from 1.5mg to 4.5mg daily, often administered at bedtime to support circadian rhythm regulation and sleep quality enhancement. Integration of LDN with caloric restriction protocols, structured physical activity programs, and comprehensive lifestyle modifications can amplify therapeutic benefits for weight management and metabolic syndrome, while simultaneously supporting immune system function and hormonal equilibrium. Beyond its established role in weight management protocols, LDN has demonstrated significant therapeutic promise for enhancing insulin sensitivity, reducing systemic inflammatory markers, and supporting endocrine balance optimization. Current research investigations continue exploring its therapeutic potential for managing severe symptomatology in conditions such as multiple sclerosis and other autoimmune pathologies, representing exciting developments in integrative medicine applications. Ultimately, while low dose naltrexone provides a promising evidence-based therapeutic option for individuals managing excess adiposity, metabolic syndrome, or chronic pain conditions, it does not replace comprehensive lifestyle interventions fundamental to integrative medicine practice. A holistic treatment approach incorporating nutritional modifications, regular physical activity protocols, and stress management techniques remains essential for achieving sustained long-term therapeutic success. Through collaborative partnership with qualified healthcare providers and dedicated adherence to established treatment protocols, patients can maximize LDN's therapeutic benefits while maintaining optimal safety profiles. Should any severe symptomatology develop or concerns regarding adverse effects arise, prompt communication with your healthcare provider ensures appropriate clinical guidance and intervention. Patient Perspectives and Experiences Many patients struggling with weight management have turned to low dose naltrexone as part of a comprehensive approach, particularly when conventional methods haven't produced lasting results. People dealing with obesity alongside conditions like insulin resistance, PCOS, hypothyroidism, or chronic inflammation frequently report reduced cravings, improved appetite control, better sleep, and enhanced energy levels that support their weight loss efforts. Clinical observations align with these reports. Patients often describe feeling less driven by food cravings and finding it easier to maintain dietary changes. Some note improvements in mood and reduced emotional eating patterns—factors that often undermine weight loss attempts. Beyond the number on the scale, practitioners have documented improvements in metabolic markers and overall well-being. For many patients, LDN has helped address the inflammatory and hormonal imbalances that can make weight loss particularly challenging. Patients sometimes describe LDN as a helpful tool that makes sustainable lifestyle changes feel more achievable. The mechanism appears to involve immune modulation, improved insulin sensitivity, and normalization of appetite signaling. That said, responses to LDN vary considerably. While many patients benefit, some don't achieve meaningful results. Weight loss with LDN still requires a caloric deficit and commitment to dietary and lifestyle changes—it supports rather than replaces these fundamentals. Consultation with a knowledgeable provider is essential to determine appropriateness and monitor progress. As research continues, LDN's role in metabolic health and weight management will become better defined—offering another option for patients seeking integrative approaches to sustainable weight loss. Resources Facebook LDN Support Group: https://www.facebook.com/groups/2927649837416056 LDN Support Group Website: www.ldnsupportgroup.com Dr. Kim's LDN Blog: https://www.directintegrativecare.com/integrative-medicine-blog Dr. Kim's LDN YouTube Channel: https://www.youtube.com/@YoonHangKimMD Request your free copy of the LDN Primer 2025: https://www.ldnsupportgroup.org/projects-6Conclusion Low-dose naltrexone shows theoretical promise for weight loss through anti-inflammatory and metabolic pathways, yet evidence remains limited and primarily anecdotal or indirect. In contrast, the naltrexone/bupropion combination (Contrave) is well-substantiated for producing significant, sustained weight loss as an adjunct to lifestyle changes. Clinicians should consider patient-specific factors, including comorbidities and tolerance, when evaluating these options. Further RCTs are needed to clarify LDN's role in obesity treatment. Meet Dr. Yoon Hang Kim MD MPH Integrative & Functional Medicine and LDN Therapy Expert At Direct Integrative Care, Dr. Kim is dedicated to guiding you on your path to wellness through a deeply personalized and supportive approach. We focus on integrative medicine, looking beyond symptoms to uncover the root causes of chronic conditions and develop a treatment plan tailored specifically to your unique health journey. By combining compassionate care with innovative therapies, our goal is to empower you with the knowledge and tools needed to achieve lasting health. We invite you to explore our website to learn more about how our patient-centered practice can help you find balance and vitality. Yoon Hang Kim, MD Direct Integrative Care www.directintegrativecare.com Virtual Integrative Functional Tele-Medicine in IA, IL, MO, GA, FL, and TX Text and Phone 210.981.6106 Toll Free 855.462.0188 References Greenway, F. L., Fujioka, K., Plodkowski, R. A., Mudaliar, S., Guttadauria, M., Erickson, J., Kim, D. D., & Dunayevich, E. (2010). Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet , 376(9741), 595–605. https://doi.org/10.1016/S0140-6736(10)60888-4 Kulak-Bejda, A., Bejda, G., & Waszkiewicz, N. (2021). Safety and efficacy of naltrexone for weight loss in adult patients – a systematic review. Archives of Medical Science , 17(4), 920–929. https://doi.org/10.5114/aoms.2020.100183 Wadden, T. A., Foreyt, J. P., Foster, G. D., Hill, J. O., Klein, S., O'Neil, P. M., Perri, M. G., Pi-Sunyer, F. X., Rock, C. L., Erickson, J. S., Maier, H. N., Kim, D. D., & Dunayevich, E. (2011). Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: The COR-BMOD trial. Obesity , 19(1), 110–120. https://doi.org/10.1038/oby.2010.147 Younger, J., Parkitny, L., & McLain, D. (2014). The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clinical Rheumatology , 33(4), 451–459. https://doi.org/10.1007/s10067-014-2517-2

Edited by Yoon Hang Kim MD MPH About Dr. Kim Dr. Yoon Hang "John" Kim, a recipient of the 2024 Functional Medicine for All scholarship from the Institute for Functional Medicine, brings over 20 years of experience in integrative and functional medicine to his telemedicine practice. After serving as chief wellness officer at a community hospital in Carthage, IL, where he provided care to rural and underserved populations, Dr. Kim now offers virtual integrative and functional medicine services, making personalized, evidence-based care accessible to patients regardless of location. His approach combines functional medicine lab testing with complementary therapies such as meditation, yoga, tai chi, and lifestyle interventions using food and physical activity as medicine, addressing the root causes of disease. Dr. Kim earned his medical degree from the Medical College of Wisconsin, completed a master’s in public health at San Diego State University, and trained with Dr. Andrew Weil during his residential fellowship at the University of Arizona. Certified by the American Board of Preventive Medicine, the American Board of Medical Acupuncture, and the American Board of Integrative and Holistic Medicine, he has also contributed to the field as a faculty member, consultant, and founder of the Integrative Health Studies Certificate program at the University of West Georgia. With clinical interests in autoimmune conditions, chronic pain, integrative oncology, and gastrointestinal disorders, Dr. Kim specializes in treating complex conditions such as fibromyalgia, chronic fatigue syndrome, long COVID symptoms, and toxic mold illness, and has authored two books and over 20 articles while helping establish integrative medicine practices across various institutions. Professional Inquiries: www.yoonhangkim.com Clinical Inquiries: www.directintegrativecare.com Abstract Low-dose naltrexone (LDN), typically administered at 1–4.5 mg daily, has gained attention for off-label applications beyond its standard use in alcohol use disorder (AUD). While standard-dose naltrexone (50 mg daily) is well established for reducing heavy drinking and cravings in AUD, evidence supporting LDN specifically for alcohol cessation or reduction remains limited and preliminary. This article reviews the mechanistic distinctions, available clinical data, and practical considerations surrounding LDN in AUD, emphasizing the need for caution and professional oversight. Introduction Alcohol use disorder (AUD) affects millions worldwide and contributes substantially to morbidity and mortality. Pharmacologic interventions, including naltrexone, acamprosate, and disulfiram, are recommended as adjuncts to psychosocial therapies (Reus et al., 2018). Standard-dose naltrexone, an opioid receptor antagonist, is FDA-approved for AUD at 50 mg daily, where it reduces alcohol-related reward and craving (Maisel et al., 2013; Jonas et al., 2014). In contrast, low-dose naltrexone (LDN) is thought to exert effects through transient opioid receptor blockade and subsequent endorphin modulation, mechanisms primarily studied in chronic pain, inflammatory, and autoimmune conditions (Younger et al., 2014). Most published research and clinical trials on LDN have focused on its use in chronic conditions and autoimmune diseases, with organizations like the LDN Research Trust supporting research and education in this area. Interest has recently emerged regarding LDN’s potential role in AUD, particularly for craving reduction or moderated drinking, though high-quality evidence remains sparse. Mechanisms of Action on Opioid Receptors At standard doses, naltrexone competitively blocks μ-opioid receptors, reducing alcohol-induced dopamine release within mesolimbic reward pathways and thereby diminishing reinforcement (O’Malley et al., 2002). LDN, administered at substantially lower doses, is hypothesized to induce a compensatory increase in endogenous opioid production or to modulate neuroinflammation via glial cell activity (Toljan & Vrooman, 2018). Specifically, LDN may act on microglial cells within the central nervous system, which are key glial cells involved in neuroinflammation. Activated microglial cells produce proinflammatory cytokines, pro inflammatory cytokines, nitric oxide, reactive oxygen species, and substance P, all of which contribute to pain, inflammation, and neurotoxicity. LDN may help suppress microglial activation, thereby reducing the production of these inflammatory mediators. Additionally, LDN’s transient blockade of opioid receptors can lead to increased production of endogenous opioids and natural peptides, such as endorphins and opioid growth factor. These natural peptides interact with opioid growth factor receptors to regulate immune function and cell growth. Opioid receptors are present in both the central and peripheral nervous systems, so LDN’s effects may extend to both regions. While these mechanisms may plausibly influence craving or affective regulation, they remain speculative in the context of AUD and have not been directly validated in alcohol-specific models. Evidence for Standard-Dose Naltrexone in AUD Multiple meta-analyses demonstrate moderate efficacy for oral naltrexone 50 mg daily in reducing return to heavy drinking, with a number needed to treat of approximately 12, and in decreasing drinking days when combined with psychosocial interventions (Jonas et al., 2014; Maisel et al., 2023). Clinical practice guidelines from the American Psychiatric Association endorse its use for individuals with moderate-to-severe AUD (Reus et al., 2018). Evidence for Low-Dose Naltrexone in AUD and Chronic Pain Direct evidence evaluating LDN for AUD is limited. Available data consist primarily of anecdotal reports, theoretical discussions, and small exploratory studies. To date, no large randomized controlled trials demonstrate efficacy for LDN in alcohol cessation or reduction (Patten et al., 2024). One pilot study—a pilot randomized trial—assessing LDN in combination with gabapentin among individuals with HIV and heavy alcohol use found no significant difference in pain or alcohol-related outcomes compared with placebo (Edelman et al., 2024). While off-label discussions frequently cite potential reductions in cravings, these claims remain unsupported by rigorous clinical evidence (Toljan & Vrooman, 2018). Crossover trials have been used in other LDN research, such as studies on fibromyalgia, to assess efficacy, but such study designs are lacking in the context of AUD. Limitations and Risks LDN is not FDA-approved for AUD, and its use in this context constitutes off-label prescribing. Although side effects are generally mild—such as insomnia or vivid dreams—potential risks include hepatic strain, particularly with ongoing alcohol consumption. It is important to note that opioid antagonist naltrexone is FDA-approved for opioid use disorder, where higher dosages are typically used compared to low dose naltrexone. Taking LDN or naltrexone while opioids are present in the system can precipitate opioid withdrawal, so medical screening is essential before starting therapy. Self-directed use is discouraged due to variability in compounding practices, dosing, and potential drug interactions. Patient Perspectives and Experiences - Please consider joining FB LDN Support Group - https://www.facebook.com/groups/2927649837416056 LDN Support Group Website: www.ldnsupportgroup.com Dr. Kim's LDN Blog - https://www.directintegrativecare.com/integrative-medicine-blog Dr. Kim's LDN YouTube Channel - https://www.youtube.com/@YoonHangKimMD Request Free LDN Primer Check out the link below to request your free copy of the LDN Primer 2025!   https://www.ldnsupportgroup.org/projects-6 Many patients with chronic pain conditions have turned to low dose naltrexone (LDN) as an anti-inflammatory treatment, particularly when conventional approaches haven't provided adequate relief. People with fibromyalgia, complex regional pain syndrome, and multiple sclerosis frequently report improvements in function, reduced pain intensity, better sleep, and enhanced quality of life. Clinical research supports these observations. In randomized placebo-controlled trials, fibromyalgia patients taking LDN showed significant reductions in pain severity, fatigue, and sleep disruption. Patients with Crohn's disease have reported improvements in abdominal pain, diarrhea frequency, and fatigue—demonstrating LDN's potential across multiple inflammatory conditions. Beyond pain relief, practitioners have documented improvements in psychological well-being, with patients showing meaningful reductions in anxiety and depression scores alongside physical symptom improvement. For many, LDN has also helped reduce opioid dependence—addressing legitimate concerns about addiction risks and long-term side effects of chronic opioid use. Patients often describe LDN as transformative, enabling greater participation in daily activities and improved overall function. The mechanism appears to involve immune modulation, resulting in decreased inflammation and better health outcomes. That said, responses to LDN vary considerably. While many patients benefit, some don't achieve meaningful improvement. As with any treatment, consultation with a knowledgeable provider is essential to determine appropriateness and monitor for adverse reactions. As research continues, LDN's role in chronic pain and inflammatory conditions will become better defined—offering hope for patients seeking alternatives to conventional pain management. Conclusion While standard-dose naltrexone has a well-established evidence base for the treatment of alcohol use disorder, current data are insufficient to support the use of low-dose naltrexone for reducing alcohol consumption or cravings. Individuals interested in pharmacologic treatment for AUD should consult qualified healthcare professionals to pursue evidence-based options and integrate medication with behavioral and psychosocial interventions. About Dr. Kim's Private Practice At Direct Integrative Care, Dr. Kim is dedicated to guiding you on your path to wellness through a deeply personalized and supportive approach. We focus on integrative medicine, looking beyond symptoms to uncover the root causes of chronic conditions and develop a treatment plan tailored specifically to your unique health journey. By combining compassionate care with innovative therapies, our goal is to empower you with the knowledge and tools needed to achieve lasting health. We invite you to explore our website to learn more about how our patient-centered practice can help you find balance and vitality.  Yoon Hang Kim MD Integrative & Functional Medicine Physician Virtual Practice Serving IA, IL, MO, FL, GA, and TX www.directintegrativecare.com References Edelman, E. J., et al. (2024). Pilot RCT comparing low-dose naltrexone, gabapentin and placebo to reduce pain among people with HIV with alcohol problems. PLOS ONE, 19 (2), e0297903. https://doi.org/10.1371/journal.pone.0297903 Jonas, D. E., et al. (2014). Pharmacotherapy for adults with alcohol use disorders in outpatient settings: A systematic review and meta-analysis. JAMA, 311 (18), 1889–1900. https://doi.org/10.1001/jama.2014.3628 Maisel, N. C., et al. (2013). Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: When are these medications most helpful? Addiction, 108 (2), 275–293. https://doi.org/10.1111/j.1360-0443.2012.04054.x Maisel, N. C., et al. (2023). Pharmacotherapy for alcohol use disorder: A systematic review and meta-analysis. JAMA Network Open, 6 (11), e2343420. O'Malley, S. S., et al. (2002). Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis. Psychopharmacology, 160 (1), 19–29. Patten, D. K., et al. (2024). Low-dose naltrexone: A potential gold medalist? American Family Physician, 110 (2), 123–124. Reus, V. I., et al. (2018). The American Psychiatric Association practice guideline for the pharmacological treatment of patients with alcohol use disorder. American Journal of Psychiatry, 175 (1), 86–90. https://doi.org/10.1176/appi.ajp.2017.1750101 Toljan, K., & Vrooman, B. (2018). Low-dose naltrexone (LDN)—Review of therapeutic utilization. Medical Sciences, 6 (4), 82. https://doi.org/10.3390/medsci6040082 Younger, J., et al. (2014). The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clinical Rheumatology, 33 (4), 451–459.

Exploring the Potential Role of Low-Dose Naltrexone in Seizure Management: Emerging Evidence from Preclinical and Preliminary Clinical Studies Edited by Yoon Hang Kim MD MPH Low-dose naltrexone (LDN), typically administered at doses of 1–5 mg daily, represents an off-label application of a medication originally approved for opioid and alcohol dependence at higher doses (50 mg). Recent investigations have explored its potential anticonvulsant properties, primarily through modulation of neuroinflammation, glial activity, and opioid receptor signaling. These effects are thought to arise from transient blockade of toll-like receptor 4 (TLR4) on microglial cells, leading to reduced proinflammatory cytokine release and attenuation of excitotoxic pathways implicated in epileptogenesis. Preclinical research in animal models has provided the foundational evidence for these effects. In zebrafish larvae modeling Dravet syndrome (scn1Lab mutants) and pentylenetetrazole (PTZ)-induced seizures, naltrexone significantly reduced abnormal locomotion and seizure-like behavior. Similar anticonvulsant activity was observed in mouse models, including decreased seizure-like events in acute brain slices, reduced duration and frequency of PTZ-induced convulsive seizures, and complete prevention of post-traumatic seizures following traumatic brain injury (TBI). In the TBI model, naltrexone also mitigated neuroinflammation (e.g., reduced IL-1β, TNFα expression), microgliosis, neurodegeneration, and oxidative stress markers, while preserving white matter integrity. Human evidence remains limited but encouraging. A small case series of pediatric patients with intractable epilepsy reported substantial reductions in seizure frequency—some achieving seizure-free status—along with electrophysiological improvements on electroencephalogram (EEG) after adjunctive LDN therapy. These observations align with hypotheses that LDN's immune-modulating properties may interrupt neuroinflammatory cascades contributing to refractory seizures. Despite these promising findings, significant caveats exist. No large-scale randomized controlled trials have confirmed efficacy or established optimal dosing for seizure disorders. Higher doses of naltrexone or combinations (e.g., with bupropion) are associated with increased seizure risk, potentially due to lowered seizure threshold in vulnerable individuals. Rare reports of seizures linked to standard-dose naltrexone underscore the need for caution. In conclusion, while preclinical data robustly support anticonvulsant and neuroprotective roles for naltrexone, and preliminary human observations suggest clinical potential, LDN cannot currently be recommended as a standard therapy for seizures or epilepsy. Its use should be confined to supervised clinical settings, prioritizing established antiepileptic drugs. Future rigorous trials are essential to delineate efficacy, safety, and mechanisms in human populations. For More Information, Join FB LDN Support Group: https://www.facebook.com/groups/2927649837416056 About The Author At Direct Integrative Care, Dr. Yoon Hang Kim MD is dedicated to guiding you on your path to wellness through a deeply personalized and supportive approach. We focus on integrative medicine, looking beyond symptoms to uncover the root causes of chronic conditions and develop a treatment plan tailored specifically to your unique health journey. By combining compassionate care with innovative therapies, our goal is to empower you with the knowledge and tools needed to achieve lasting health. We invite you to explore our website to learn more about how our patient-centered practice can help you find balance and vitality.  Yoon Hang Kim MD Integrative & Functional Medicine Physician Virtual Practice Serving IA, IL, MO, FL, GA, and TX www.directintegrativecare.com Dr. Yoon Hang Kim is an expert in Integrative & Functional Medicine and in LDN Therapy References Abokrysha, N. T., Kishk, N. A., Nawito, A. M., & Mounir, N. (2021). Effect of low-dose naltrexone on Egyptian children with intractable epilepsy: A case series study. Neurology India, 69(6), 1781–1784. https://doi.org/10.4103/0028-3886.333523 Rodriguez, S., Sharma, S., Tiarks, G., & Glykys, J. (2024). Neuroprotective effects of naltrexone in a mouse model of post-traumatic seizures. Scientific Reports, 14, Article 13507. https://doi.org/10.1038/s41598-024-63942-8 Sturgeon, M. L., Langton, R., Sharma, S., Cornell, R. A., Glykys, J., & Bassuk, A. G. (2021). The opioid antagonist naltrexone decreases seizure-like activity in genetic and chemically induced epilepsy models. Epilepsia Open, 6(3), 528–538. https://doi.org/10.1002/epi4.12512

Introduction Treatment-resistant epilepsy, defined as the persistence of seizures despite adequate trials of at least two appropriately selected antiepileptic drugs, affects approximately one-third of individuals with epilepsy. Focal seizures, which originate from a specific brain region, are a common subtype and often present significant management challenges. Functional and integrative medicine frameworks emphasize individualized interventions that address potential underlying contributors such as inflammation, metabolic dysfunction, nutrient deficiencies, and lifestyle factors. These approaches are intended to complement conventional pharmacotherapy and are supported by varying levels of evidence. This review outlines key integrative strategies, including dietary therapies, nutritional supplementation, mind-body practices, and other complementary modalities. Dietary Interventions The ketogenic diet and its variants, including the modified Atkins diet and low glycemic index treatment, represent the most well-supported non-pharmacologic interventions for drug-resistant epilepsy, including focal seizures. These dietary approaches induce ketosis, which may stabilize neuronal excitability through anti-inflammatory mechanisms and modulation of neurotransmitter balance. A Cochrane review of randomized controlled trials demonstrated improved seizure outcomes, including seizure freedom and reductions of at least 50 percent in seizure frequency, compared with usual care in both pediatric and adult populations. Nutritional Supplementation Functional medicine approaches often focus on identifying and correcting nutrient deficiencies that may contribute to seizure susceptibility. Functional medicine labs provide for an opportunity to explore root causes and then address the root causes. Omega-3 fatty acids have anti-inflammatory properties, and meta-analyses suggest they may modestly reduce seizure frequency in individuals with epilepsy. Magnesium has been explored for its role in neuronal membrane stabilization, although current evidence remains largely theoretical and preliminary. Vitamin D deficiency is common among epilepsy patients, in part due to antiepileptic drug effects on metabolism, and correction may improve seizure control and quality of life. Cannabidiol, particularly pharmaceutical-grade formulations, has demonstrated efficacy as an adjunctive therapy in refractory focal epilepsy, with evidence supporting meaningful reductions in seizure burden. All supplementation strategies should be guided by laboratory assessment and clinical oversight to minimize risk and drug interactions. Lifestyle and Mind-Body Practices Stress is a well-recognized seizure precipitant, supporting the integration of stress-modulating interventions into comprehensive epilepsy care. Yoga and meditation have been associated with reductions in seizure frequency and improvements in quality of life, likely mediated through autonomic nervous system regulation and stress reduction. Acupuncture, when used as an adjunct to conventional treatment, has shown potential benefit in reducing seizure frequency, possibly through effects on thalamic signaling and neuroinflammatory pathways. These modalities are generally low risk when appropriately implemented. Other Complementary Approaches Additional holistic strategies, including selected herbal therapies, have been explored in epilepsy care, though high-quality evidence remains limited. Integrative treatment plans emphasize safety and careful evaluation of potential interactions with antiepileptic medications, prioritizing approaches with the most favorable risk-benefit profiles. Conclusion Integrative and functional medicine strategies may offer valuable adjunctive options for individuals with treatment-resistant focal seizures, particularly when conventional therapies alone are insufficient. Among these approaches, dietary interventions, especially ketogenic-based therapies, have the strongest evidence base. Nutritional supplementation and mind-body practices may provide additional benefit when individualized and clinically supervised. Collaboration with neurologists experienced in integrative care is essential to ensure safe, evidence-informed implementation. Yoon Hang Kim MD MPH is an expert in integrative and functional medicine and LDN therapy. Integrative and Functional Medicine Approaches to Treatment-Resistant Focal Seizures San Antonio | | Direct Integrative Care At Direct Integrative Care, Dr. Kim is dedicated to guiding you on your path to wellness through a deeply personalized and supportive approach. We focus on integrative medicine, looking beyond symptoms to uncover the root causes of chronic conditions and develop a treatment plan tailored specifically to your unique health journey. By combining compassionate care with innovative therapies, our goal is to empower you with the knowledge and tools needed to achieve lasting health. We invite you to explore our website to learn more about how our patient-centered practice can help you find balance and vitality.  Yoon Hang Kim MD Integrative & Functional Medicine Physician Virtual Practice Serving IA, IL, MO, FL, GA, and TX www.directintegrativecare.com References Martin-McGill, K. J., Bresnahan, R., Levy, R. G., & Cooper, P. N. (2020). Ketogenic diets for drug-resistant epilepsy. Cochrane Database of Systematic Reviews , (6), Article CD001903. https://doi.org/10.1002/14651858.CD001903.pub5 Pourmasoumi, M., Vosoughi, N., Derakhshandeh Rishehri, S., Assarroudi, M., & Fatahi, S. (2021). The effect of omega-3 fatty acid supplementation on seizure frequency in individuals with epilepsy: A systematic review and meta-analysis. Nutritional Neuroscience , 24(11), 869–878. https://doi.org/10.1080/1028415X.2020.1804094 Yuen, A. W. C., & Sander, J. W. (2012). Can magnesium supplementation reduce seizures in people with epilepsy? A hypothesis. Epilepsy Research , 100(1–2), 152–156. https://doi.org/10.1016/j.eplepsyres.2012.02.003 Chassoux, F., Artiges, E., Semah, F., et al. (2024). Vitamin D deficiency and effect of treatment on seizure frequency and quality of life parameters in patients with drug-resistant epilepsy: A randomized clinical trial. Epilepsia , 65(9), 2578–2590. https://doi.org/10.1111/epi.18050 Panesar, K., & Panebianco, M. (2023). Yoga for epilepsy. Cochrane Database of Systematic Reviews , (10), Article CD001524. https://doi.org/10.1002/14651858.CD001524.pub4 Liu, Y., Li, Y., Zhang, X., et al. (2023). Effectiveness of acupuncture as auxiliary combined with Western medicine for epilepsy: A systematic review and meta-analysis. Frontiers in Neuroscience , 17, Article 1203231. https://doi.org/10.3389/fnins.2023.1203231 de Oliveira, V. G., de Almeida, N. B., Radmann, G. C., et al. (2025). The efficacy of cannabidiol for seizure reduction in pharmacoresistant epilepsy: A systematic review and meta-analysis. Acta Epileptologica , 7, Article 20. https://doi.org/10.1186/s42494-024-00191-2 Kuchenbuch, M., Lassalle, M., Pons, C., et al. (2023). Use of integrative, complementary, and alternative medicine in children with epilepsy: A global scoping review. Children , 10(4), Article 713. https://doi.org/10.3390/children10040713

A Review of Mechanisms, Evidence, and Clinical Considerations Edited by Yoon Hang Kim MD, MPH Dr. Yoon Hang Kim, MD, is a renowned clinical expert in Low-Dose Naltrexone (LDN) and a sought-after presenter at the LDN Research Trust Conference. As an integrative and functional medicine physician, Dr. Kim brings a holistic approach to patient care, combining evidence-based practices with innovative therapies like LDN. He is the author of a book on LDN, which covers its therapeutic potential across various conditions, and has also contributed an insightful article on the subject of using LDN for treating pain.Dr. Kim’s work not only highlights the science behind LDN but also emphasizes its practical application in improving patient outcomes.  Dr. Kim also has a YouTube channel focusing on LDN therapy and also serves as an administrator for LDN Support Group. Video is related to blog article by subject only. Dr. Kim speaks his experience. 1. Introduction Fibromyalgia is a chronic pain syndrome affecting an estimated 2–4% of the global population, with a marked female predominance. My first introduction to the multi-dimensional aspect of fibromyalgia occurred before my discovering LDN.  At that time, utilizing acupuncture neurology (a specialty technique within acupuncture) to reset pain yielded about 50% pain control.  The other 30% came from resolution of an  internal conflict resolved through her faith.  The condition is characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, and cognitive difficulties often referred to as "brain fog." Despite its prevalence, fibromyalgia remains one of the most challenging conditions to treat effectively in conventional medicine. Current pharmacological approaches—including pregabalin, duloxetine, and milnacipran—offer modest efficacy at best, with meta-analyses suggesting only 30–40% of patients achieve meaningful symptom reduction. Furthermore, these medications frequently produce significant adverse effects including weight gain, cognitive impairment, sedation, and sexual dysfunction, leading to poor adherence and treatment discontinuation. This therapeutic gap has prompted investigation into alternative approaches, among which Low-Dose Naltrexone (LDN) has emerged as a particularly promising candidate. This article examines the scientific rationale, clinical evidence, and practical considerations for LDN in fibromyalgia management. 2. What is Low-Dose Naltrexone (LDN)? 2.1 Pharmacological Background Naltrexone is an opioid receptor antagonist originally approved by the FDA in 1984 at doses of 50–100 mg daily for the treatment of opioid and alcohol use disorders. At these standard doses, naltrexone provides sustained blockade of mu-opioid receptors, preventing the euphoric effects of exogenous opioids and reducing alcohol cravings. Low-Dose Naltrexone refers to the off-label use of naltrexone at doses typically ranging from 0.1 mg to 4.5 mg daily. At these lower doses, naltrexone appears to exhibit fundamentally different pharmacodynamic properties, producing transient rather than sustained opioid receptor blockade and engaging additional receptor systems and cellular mechanisms. 2.2 Proposed Mechanisms of Action The therapeutic effects of LDN in chronic pain conditions appear to operate through multiple complementary pathways.  Anti-inflammatory pathway: First, LDN modulates glial cell activity by antagonizing Toll-like receptor 4 (TLR4) on microglia and astrocytes. This antagonism reduces the introduction of pro-inflammatory cytokines including interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), while simultaneously promoting the release of anti-inflammatory mediators. Endorphin pathway: Second, the brief opioid receptor blockade induced by LDN triggers a compensatory upregulation of endogenous opioid production and receptor sensitivity during the "rebound" period after the drug's effects dissipate. This enhanced endorphin system activity may contribute to improved pain modulation and mood regulation. Immune Modulation pathway: Third, emerging evidence suggests LDN may influence regulatory T-cell function and modulate broader immune system activity, potentially addressing the immune dysregulation increasingly recognized as a feature of fibromyalgia pathophysiology. 2.3 Off-Label Applications Beyond fibromyalgia, LDN has been investigated in numerous chronic pain and autoimmune conditions including multiple sclerosis, Crohn's disease, complex regional pain syndrome, and various autoimmune disorders. While the evidence base varies across conditions, the accumulating clinical experience has informed our understanding of LDN's therapeutic potential and more importantly, it speaks to the safety profile LDN. 3. The Science Behind LDN and Fibromyalgia 3.1 Fibromyalgia Pathophysiology: Current Understanding Contemporary models of fibromyalgia pathophysiology emphasize central sensitization—a state of heightened excitability in spinal and supraspinal pain-processing circuits that amplifies nociceptive signaling and reduces descending inhibitory control. Functional neuroimaging studies consistently demonstrate altered pain processing in fibromyalgia patients, with enhanced activation of pain-related brain regions in response to normally non-painful stimuli. Increasingly, neuroinflammation has been recognized as a potential driver of central sensitization in fibromyalgia. Positron emission tomography (PET) studies using radioligands that bind to translocator protein (TSPO)—a marker of activated glial cells—have demonstrated elevated microglial activation in multiple brain regions of fibromyalgia patients compared to healthy controls. Additionally, cerebrospinal fluid analyses have revealed elevated concentrations of pro-inflammatory cytokines and chemokines in fibromyalgia patients, further supporting the neuroinflammatory hypothesis. These inflammatory mediators can directly sensitize nociceptive neurons, disrupt inhibitory neurotransmission, and contribute to the cognitive and mood disturbances characteristic of the condition. 3.2 How LDN Addresses Fibromyalgia Mechanisms LDN's proposed mechanism of action aligns remarkably well with current understanding of fibromyalgia pathophysiology. By reducing microglial activation and pro-inflammatory cytokine production, LDN may directly address the neuroinflammatory component of central sensitization. The reduction of IL-1β and TNF-α levels could decrease nociceptive neuron sensitization and restore more normal pain processing. I share with my patients that LDN appears to calm neuroinflammation. Furthermore, LDN's effects on the endogenous opioid system may help restore the dysfunctional descending pain inhibition observed in fibromyalgia. Studies have demonstrated reduced mu-opioid receptor availability in key pain-modulating brain regions of fibromyalgia patients, and the receptor upregulation induced by LDN could potentially compensate for this deficit. The multi-modal mechanism of LDN—simultaneously targeting neuroinflammation, central sensitization, and endogenous analgesia—may explain its clinical efficacy in a condition characterized by such complex and interconnected pathophysiology. 4. Key Research Studies 4.1 Younger's Pilot Study (2009) The first clinical investigation of LDN specifically for fibromyalgia was conducted by Dr. Jarred Younger and colleagues at Stanford University. This single-blind, crossover pilot study enrolled ten women with fibromyalgia who received 4.5 mg of naltrexone daily for eight weeks, with daily symptom assessments using handheld computers. Results demonstrated a 30% reduction in fibromyalgia symptoms compared to placebo, with the most pronounced effects observed for pain, fatigue, and overall sense of well-being. The placebo response is important to document as it is known in other therapies such as acupuncture.  Most importantly, the treatment was well-tolerated, with no serious adverse events reported. These promising findings provided the foundation for more rigorous investigation. 4.2 Younger's Randomized Controlled Trial (2013) Building on the pilot data, Younger and colleagues conducted a randomized, double-blind, placebo-controlled, crossover trial published in Pain Medicine in 2013. The study enrolled 31 women with fibromyalgia who received both LDN 4.5 mg daily and placebo for 12 weeks each, separated by a 4-week washout period. The primary outcome—daily self-reported pain—showed a statistically significant reduction during LDN treatment compared to placebo. Secondary analyses revealed improvements in general satisfaction with life and mood, though fatigue and sleep parameters did not reach statistical significance. Notably, participants with higher baseline erythrocyte sedimentation rates (ESR), suggesting greater systemic inflammation, demonstrated the greatest response to LDN treatment. This finding supports the hypothesis that LDN's anti-inflammatory properties may be particularly relevant to its analgesic effects in fibromyalgia. The study also confirmed LDN's favorable safety profile, with vivid dreams being the most commonly reported adverse effect. 4.3 Inflammatory Marker Studies Parkitny and Younger (2017) published an important mechanistic study examining the effects of LDN on peripheral inflammatory markers in fibromyalgia patients. Their analysis revealed significant reductions in multiple pro-inflammatory cytokines during LDN treatment, providing direct evidence for the proposed anti-inflammatory mechanism. These findings were particularly significant because they demonstrated that LDN's effects extend beyond symptomatic improvement to measurable changes in inflammatory biomarkers. This mechanistic validation strengthens the scientific rationale for LDN use in fibromyalgia and other conditions characterized by chronic inflammation. 4.4 Additional Supporting Evidence Beyond the controlled trials, substantial observational and clinical experience has accumulated supporting LDN's efficacy in fibromyalgia. Retrospective analyses and case series from multiple clinical centers have reported response rates ranging from 50–70% in fibromyalgia patients treated with LDN, often in individuals who had failed multiple conventional therapies. Experimental pain studies have demonstrated that LDN reduces temporal summation of pain (a marker of central sensitization) and mechanical hyperalgesia in laboratory models. These findings provide additional mechanistic support for LDN's effects on central pain processing. 5. Insights from the LDN Research Trust The LDN Research Trust was founded by a colleague - Linda Elsegood.  Along with Dr. Bihari, Linda transformed LDN from an obscure medication to the prominent medication well known, gaining even more popularity, and most importantly organized researchers, clinicians, and patients together through conferences, podcasts, and on-line. The last in-person conference was completed in 2025 with promise of on-line and in-real-life gathering in 2027. The LDN Research Trust has played a pivotal role in advancing awareness, research, and clinical application of LDN for fibromyalgia and other chronic conditions. Founded in 2004, this nonprofit organization has facilitated international collaboration among researchers, clinicians, and patients interested in LDN therapy. Through annual conferences bringing together leading researchers and clinicians, the LDN Research Trust has created a forum for sharing clinical experiences, research findings, and best practices. The organization maintains an extensive database of patient testimonials and case studies, providing valuable real-world evidence complementing formal clinical trials. Patient testimonials collected through the LDN Research Trust consistently report improvements in pain levels, energy, cognitive function, and overall quality of life. Many fibromyalgia patients describe LDN as "life-changing," particularly those who had experienced years of inadequate relief from conventional treatments. While such testimonials cannot substitute for controlled trials, they provide meaningful insights into LDN's real-world effectiveness and patient acceptability. The LDN Research Trust website ( ldnresearchtrust.org ) offers comprehensive resources for both patients and healthcare providers, including prescribing guides, compounding pharmacy directories, research summaries, and educational materials. These resources have been instrumental in facilitating informed discussions between patients and their healthcare providers about LDN therapy. 6. Benefits and Safety of LDN 6.1 Advantages Over Conventional Treatments LDN offers several distinct advantages compared to FDA-approved fibromyalgia medications. Most notably, the side effect profile of LDN is remarkably benign. Unlike pregabalin and duloxetine, LDN is not associated with weight gain, cognitive impairment, or sexual dysfunction—adverse effects that frequently lead to treatment discontinuation with conventional therapies. Additionally, LDN has no known abuse potential or addiction liability. As an opioid antagonist rather than agonist, it cannot produce euphoria or physical dependence. This safety characteristic is particularly valuable given the current concerns about prescription medication misuse and the challenges many fibromyalgia patients face in obtaining adequate pain treatment. Cost represents another significant advantage. Compounded LDN typically costs about one dollar per pill without insurance coverage. Today, the costs tend to be still this range even with inflation with price variance in various pharmacies.  This affordability enhances accessibility for patients, particularly those with limited insurance coverage or high deductibles. 6.2 Common Side Effects The most frequently reported adverse effect of LDN is vivid or unusual dreams, occurring in approximately 37% of patients in clinical trials. This effect typically diminishes within one to two weeks of treatment and rarely necessitates discontinuation. Some clinicians recommend taking LDN in the morning rather than evening if vivid dreams prove troublesome. Other reported side effects include mild headache, nausea, and transient anxiety, each occurring in fewer than 10% of patients. These effects are typically mild, self-limiting, and resolve with continued treatment or minor dose adjustments. Serious adverse events have not been reported in LDN clinical trials. 6.3 Safety Profile and Contraindications LDN demonstrates an excellent safety profile across numerous clinical studies and decades of use. However, certain contraindications warrant careful consideration. Ultra low dose naltrexone (1 microgram or lower) should be used in patients currently taking opioid medications.  Regular LDN dose as the antagonist effect could precipitate acute withdrawal symptoms. Because half-life of naltrexone is between 4 to 6 hours.  I believe as short as 4 to 5 half lives 16 - 30 hours should suffice as washout period for opioid using surgical preparation.  Longer wash out period of 72  hours would more likely to assure that LDN would not affect opioid medications.  Patients with active liver disease should use LDN with caution, as naltrexone is hepatically metabolized. While hepatotoxicity has been reported with standard-dose naltrexone (50–300 mg daily), this has not been observed at the low doses used in LDN therapy. Nonetheless, baseline liver function assessment is prudent in patients with known hepatic pathology. LDN use during pregnancy and lactation has not been systematically studied, and most clinicians recommend discontinuation during pregnancy unless the benefits clearly outweigh potential risks. 7. Practical Considerations for Clinical Use 7.1 Dosing Protocol The standard approach to LDN initiation involves gradual dose titration to minimize initial side effects and identify the optimal therapeutic dose for each patient. Most practitioners begin with 0.1 mg to 0.5 mg daily, taken at bedtime, and increase the dose every one to four weeks until reaching the target dose of 4.5 mg daily. Some patients experience optimal effects at doses below 4.5 mg, while others may benefit from doses up to 6, 9, or 12 mg daily. Individualization based on clinical response and tolerability is critical. Therapeutic effects may not become apparent for four to twelve weeks, necessitating patient education about realistic expectations and the importance of consistent adherence during the trial period. For patients with particular sensitivity or those with complex conditions such as mast cell activation syndrome, ultra-low-dose initiation strategies may be warranted, starting at doses as low as 0.001 mg or 1 microgram with very gradual titration. 7.2 Accessing LDN Because LDN is not available as a commercial preparation at the required doses, it must be obtained from a compounding pharmacy. Naltrexone tablets are available in 50 mg strength, but these cannot simply be divided to achieve the low doses required—precise compounding is necessary for accurate dosing. A valid prescription is required, and healthcare providers should specify the exact dose, formulation (typically immediate-release capsules), and any filler preferences. Some patients report sensitivity to certain compounding fillers, and alternative formulations may be requested if tolerability issues arise. The LDN Research Trust maintains a directory of compounding pharmacies experienced in preparing LDN, which can be a valuable resource for patients and providers seeking reliable compounding services. 7.3 Working with Healthcare Provider/Support Group Successful LDN therapy requires collaboration with a healthcare provider knowledgeable about its use. Providers experienced with LDN can offer valuable guidance on dose optimization, management of initial side effects, and integration with other treatment modalities. They can also monitor for efficacy and adjust the treatment plan as needed based on individual response. If unavailable, LDN Support Groups such as LDN Support Group can provide peer support and sharing of personal experiences. 8. Conclusion In my practice, LDN is a foundation treatment for many conditions - especially neuroinflammation and nerve pain (technically all pain involves nerve for conduction of pain.  Low-Dose Naltrexone represents a compelling treatment option for fibromyalgia patients. Its mechanisms of action—targeting neuroinflammation and central sensitization while enhancing endogenous opioid function—means an ideal treatment modality targeting multiple aspects of fibromyalgia. The clinical evidence, while still evolving, consistently demonstrates meaningful symptom reduction with an exceptionally favorable safety profile. The combination of efficacy, tolerability, non-addictive properties, and low cost positions LDN as an attractive option in the fibromyalgia treatment armamentarium. Further research, including larger randomized controlled trials and longer-term follow-up studies, will be valuable in more precisely defining LDN's role in fibromyalgia management and identifying which patient subgroups are most likely to benefit. Until such data are available, LDN is a safe and affordable alternative with favorable side effect profile. 9. References 1. Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med. 2009;10(4):663-672. 2. Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. 2013;65(2):529-538. 3. Parkitny L, Younger J. Reduced pro-inflammatory cytokines after eight weeks of low-dose naltrexone for fibromyalgia. Biomedicines. 2017;5(2):16. 4. Clauw DJ. Fibromyalgia: a clinical review. JAMA. 2014;311(15):1547-1555. 5. Loggia ML, Chonde DB, Akeju O, et al. Evidence for brain glial activation in chronic pain patients. Brain. 2015;138(Pt 3):604-615. 6. Albrecht DS, Forber C, Engström M, et al. Brain glial activation in fibromyalgia—a multi-site positron emission tomography investigation. Brain Behav Immun. 2019;75:72-83. 7. Patten DK, Schultz BG, Berlau DJ. The safety and efficacy of low-dose naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, Crohn's disease, and other chronic pain disorders. Pharmacotherapy. 2018;38(3):382-389. 8. LDN Research Trust. Resources and Research. Available at: https://ldnresearchtrust.org . Accessed 2024. 9. Harris RE, Clauw DJ, Scott DJ, McLean SA, Gracely RH, Zubieta JK. Decreased central mu-opioid receptor availability in fibromyalgia. J Neurosci. 2007;27(37):10000-10006. 10. Toljan K, Vrooman B. Low-dose naltrexone (LDN)—review of therapeutic utilization. Med Sci (Basel). 2018;6(4):82. Resources: Yoon Hang Kim MD YouTube Channel https://www.youtube.com/@YoonHangKimMD LDN Support Group Website https://www.ldnsupportgroup.org/ Support Groups Where Dr. Kim Moderates https://www.facebook.com/groups/2927649837416056 https://www.facebook.com/groups/593843748815425 https://www.reddit.com/r/LDN_LowDoseNaltrexone/ Dr. Kim’s Book: 2025 LDN Therapy: LDN plus other tools for healing https://www.amazon.com/dp/B0F9BD34MX/ref=sr_1_2?crid=78I404JYRK92&dib=eyJ2IjoiMSJ9.BEOUUagheXKWpn5VQYGq_Rxgf779cONA_59gdH3kjD9zoopGvw0lG4erfDQqCqFL.ITUWFqvtp80hz84UhldiFCeUSeW4WQuoDJcHJp50P5s&dib_tag=se&keywords=low+dose+naltrexone+ldn+yoon+hang+kim&qid=1747819520&sprefix=%2Caps%2C122&sr=8-2 Dr. Kim’s paper back book: Low Dose Naltrexone (LDN) Therapy: An Evidence Based Review and Case Histories  https://www.amazon.com/Low-Dose-Naltrexone-LDN-Therapy/dp/1977098487/ref=sr_1_4?crid=2AUCUPJCXO4SI&dib=eyJ2IjoiMSJ9.WDeq--pczYyKdBsbtir58GXbDkiXBaRoJbrun8CKQ5Nmckcz5oWNvSQ-8Sz7-6_r.Pn6eRxDB9rSEqQBjlsaadNk0OcBhvdSwqjK9wUW_kFc&dib_tag=se&keywords=low+dose+naltrexone+ldn+yoon+hang+kim&qid=1765884056&sprefix=low+dose+naltrexone+ldn+yoon+hang+kim%2Caps%2C589&sr=8-4 Various AI Tools are used by Dr. Kim who subscribes to multiple AI platforms including Grok, Claude, Jasper, and AskEasy. Additional AI used include Gemini and OpenEvidence.  Dr. Kim’s experience is that all AI platforms are capable of misrepresentation and deception - so, Dr. Kim edits these articles carefully.  This article took about 3 hours over the course of two days. Meet Dr. Kim - expert in LDN therapy, Integrative & Functional Medicine Dr. Kim's Clinic At Direct Integrative Care, Dr. Kim is dedicated to guiding you on your path to wellness through a deeply personalized and supportive approach. We focus on integrative medicine, looking beyond symptoms to uncover the root causes of chronic conditions and develop a treatment plan tailored specifically to your unique health journey. By combining compassionate care with innovative therapies, our goal is to empower you with the knowledge and tools needed to achieve lasting health. We invite you to explore our website to learn more about how our patient-centered practice can help you find balance and vitality.  Yoon Hang Kim MD Integrative & Functional Medicine Physician Virtual Practice Serving IA, IL, MO, FL, GA, and TX www.directintegrativecare.com

When LDN does not work Yoon Hang Kim MD By Yoon Hang Kim, MD, MPH Direct Integrative Care www.directintegrativecare.com Introduction Low-dose naltrexone (LDN) has emerged as a promising therapeutic option for numerous chronic conditions, from fibromyalgia and chronic pain to autoimmune disorders and mast cell activation syndrome. As a physician who has been prescribing LDN for over two decades and has presented at multiple LDN Research Trust conferences, I have witnessed its remarkable benefits in many patients. However, I have also observed a clinical reality that warrants honest discussion: approximately one-third of patients do not respond to standard LDN therapy. This observation aligns with published literature showing response rates typically ranging from 57-65% in various chronic pain populations (Kim et al., 2023; Younger et al., 2013). Understanding why LDN fails—and what to do about it—is crucial for clinicians seeking to optimize outcomes for their patients. Understanding the LDN Response Spectrum In my clinical experience, patients fall into three distinct categories when it comes to LDN therapy: Category 1: LDN as Sufficient Therapy For some patients, LDN alone produces profound and sustained improvement. These patients typically have: Adequate baseline endorphin reserves Moderate disease severity Conditions primarily driven by neuroinflammation or immune dysregulation Good overall functional capacity Research supports that LDN can be highly effective as monotherapy in conditions like fibromyalgia, where studies have demonstrated a 28.8% reduction in pain compared to 18% with placebo (Younger et al., 2013). A retrospective analysis from Mayo Clinic found that 65% of patients taking LDN for chronic pain reported perceived benefit (Toljan & Vrooman, 2018). Category 2: LDN as Necessary but Not Sufficient In complex cases, LDN plays a vital role but cannot achieve remission on its own. These conditions include: Mold toxicity and chronic inflammatory response syndrome (CIRS) Cancer Mast cell activation syndrome (MCAS) Long COVID Complex regional pain syndrome (CRPS) Chronic Lyme disease For these patients, LDN serves as one critical component of a multimodal treatment strategy. As noted by researchers studying MCAS, LDN does not target the root cause directly but "can calm the immune system enough to make deeper treatment more successful and better tolerated" (Restorative Medicine Center, 2024). Category 3: Non-Responders Some patients simply do not respond to LDN at any dose. This may relate to: Severely depleted endorphin reserves Genetic variations in opioid receptor function Conditions not primarily mediated by the pathways LDN modulates Co-existing factors that override LDN's mechanisms The Clinical Approach: Assessing Endorphin Reserve My clinical approach begins with estimating a patient's endorphin reserve  by assessing their functional capacity in everyday life. This concept is fundamental to personalizing LDN therapy. Assessment Questions I Consider: Duration of illness : How long have they been sick? Sleep quality : Do they achieve restorative sleep? Energy levels : What is their baseline energy throughout the day? Resilience : How quickly do they recover from setbacks? Functional capacity : Can they work, exercise, or perform daily activities? Patients with severely depleted endorphin reserves—those who are very ill or have very low functional capacity—require a different approach than the standard 4.5 mg dosing. Dosing Strategies for Challenging Cases Starting Low: Microgram Dosing For patients who are very ill, have low functional capacity, or are children, I advocate for starting at significantly lower doses  than the conventional 1.5-4.5 mg range. This approach is sometimes called ultra-low-dose naltrexone (ULDN) or very-low-dose naltrexone (VLDN). The LDN Research Trust's dosing guidelines recognize three categories (LDN Research Trust, 2024): Ultra-low dose : Microgram dosing (1-2 mcg) Very-low dose : 0.1-0.5 mg daily Low dose : 1-4.5 mg (sometimes up to 10 mg) My 2018 presentation at the LDN Research Trust Conference detailed the rationale for microgram dosing, explaining that at 1 microgram, naltrexone binds to opioid receptors but is not likely to overwhelm the system, potentially acting as a weak agonist through the phenomenon of hormesis—where a substance acts as an inhibitor at high concentrations but as a stimulator at lower concentrations (Kim, 2018). The Nanogram Option For patients who cannot tolerate even microgram doses, there are options to dilute further to nanogram ranges . These preparations are not typically available from pharmacies and require specialized compounding or self-dilution protocols. While clinical evidence at this dose range is limited, some highly sensitive patients have reported benefit. Titration Protocol for Sensitive Patients For sensitive patients, I recommend: Start at 0.5-1 mg (or lower if indicated) Increase slowly over extended periods Some patients may need 2-week intervals  between dose increases Others may require 4-week intervals The most sensitive patients may need 3-month intervals  between adjustments This contrasts with typical protocols that escalate to 4.5 mg within 2-4 weeks. Patience is essential. When Standard LDN Fails: Alternative Strategies Strategy 1: Higher-Dose Naltrexone for Neuropathy If there is no response to standard LDN dosing, especially in neuropathic pain conditions , I consider: Adding ketosis support  (ketogenic diet or exogenous ketones) Increasing the dose to 25 mg or even up to 45 mg This higher-dose approach moves into "moderate-dose" territory and may work through different mechanisms than traditional LDN. A dose-response study found that the effective dose in 95% of fibromyalgia patients (ED95) was 5.40 mg, with some patients benefiting from doses up to 6 mg (Bruun et al., 2021). However, clinical experience suggests some neuropathy patients respond to even higher doses. The rationale for combining with ketosis relates to the metabolic and anti-inflammatory effects of ketone bodies, which may synergize with naltrexone's mechanisms in neuropathic conditions. Strategy 2: MCAS Protocol Enhancement For complex conditions like mast cell activation syndrome (MCAS) , I consider adding: Ketotifen  (1-2 mg at bedtime, increasing as tolerated) Cromolyn sodium  (mast cell stabilizer) Methylene blue  combined with ketosis The Role of Ketotifen and Cromolyn Ketotifen is an oral mast cell stabilizer that inhibits the release of histamine, tryptase, and various prostaglandins from mast cells. It reduces antigen-induced mast cell degranulation and stabilizes calcium permeability in mast cell membranes (Rosenberg, 2022). Combined with cromolyn sodium, which works by inhibiting immediate and late-phase mast cell release, these medications can significantly improve MCAS symptoms including urticaria, nausea, diarrhea, and neurological manifestations. A landmark case study published in BMJ Case Reports demonstrated dramatic improvement in a patient with severe POTS and MCAS using a combination of LDN, intravenous immunoglobulin, and treatment of underlying small intestinal bacterial overgrowth (Weinstock et al., 2018). Methylene Blue and Mitochondrial Support Methylene blue has gained attention for its ability to enhance mitochondrial function by acting as an alternative electron carrier in the electron transport chain. It can increase ATP production, reduce oxidative stress, and decrease neuroinflammation (Yang et al., 2017). For patients with chronic fatigue, MCAS, or conditions involving mitochondrial dysfunction, methylene blue combined with ketosis may provide synergistic benefits that support overall healing alongside LDN. The Role of the Integrative Medicine Specialist There is a clear role for physicians who are well-versed in both LDN therapy and functional medicine to assist patients with complex conditions. Standard primary care providers may not have the experience to: Properly assess endorphin reserve Navigate non-standard dosing protocols Integrate complementary therapies Recognize when LDN is necessary but not sufficient Troubleshoot treatment failures As the LDN Research Trust notes, "Low Dose Naltrexone has been studied extensively since 1985. There are well over 900-950 articles, scientific papers, research papers, clinical abstracts, and double-blind studies done on Low Dose Naltrexone" (LDN Research Trust, 2024). Yet this wealth of information is not typically taught in medical schools or mainstream continuing education programs, leaving many patients without access to knowledgeable prescribers. Practical Recommendations Summary Scenario Recommended Approach Standard patient, moderate illness Start 1.5 mg, titrate to 4.5 mg over 2-4 weeks Severely ill / low functional capacity Start 0.5 mg or lower; titrate every 2-4 weeks Children Microgram dosing; very slow titration Extreme sensitivity Consider nanogram ranges; titrate every 1-3 months Side effects at low doses Drop to lower dose; slower titration Non-response in neuropathy Consider higher doses (up to 25-45 mg) + ketosis Complex MCAS Add ketotifen, cromolyn, consider methylene blue + ketosis Treatment-resistant cases Comprehensive functional medicine workup Conclusion LDN is a powerful tool in the integrative medicine toolkit, but it is not a universal solution. Approximately one-third of patients will not respond to standard protocols, and recognizing this reality is the first step toward better outcomes. By carefully assessing each patient's endorphin reserve, tailoring dosing strategies, and integrating complementary approaches when needed, we can optimize results and offer hope even to patients with treatment-resistant conditions. The key is individualization. There is no one-size-fits-all approach to LDN therapy. Whether it means starting at microgram doses for the severely depleted patient or pushing to higher doses for refractory neuropathy, the clinician must be willing to think beyond standard protocols while remaining grounded in the science. For patients struggling with complex chronic conditions, working with a physician experienced in LDN and functional medicine can make the difference between treatment failure and meaningful improvement. References Bruun, K. D., Christensen, R., Amris, K., Vaegter, H. B., & Toft, E. (2021). Low-dose naltrexone for the treatment of fibromyalgia: Protocol for a double-blind, randomized, placebo-controlled trial. Trials, 22 (1), 804. https://pmc.ncbi.nlm.nih.gov/articles/PMC8591911/ Kim, Y. H. (2018). Ultra low dose naltrexone, micro dosing [Conference presentation]. LDN Research Trust 2018 Conference. https://ldnresearchtrust.org/dr-john-kim%E2%80%99s-presentation-ultra-low-dose-naltrexone-uldn-and-micro-dosing-ldn-2018-conference LDN Research Trust. (2024). Dosing information for prescribers . https://ldnresearchtrust.org/sites/default/files/2024-02/Dosing-Guide-2024_0.pdf LDN Research Trust. (2024). Why are so many doctors resistant to low dose naltrexone?   https://ldnresearchtrust.org/why-are-so-many-doctors-resistant-low-dose-naltrexone-ldn Rosenberg, S. (2022). Ketotifen: How it works and its uses in your practice. Oregon Association of Naturopathic Physicians . https://www.mcmc-research.com/post/low-dose-naltrexone-and-mcas-treatment Takkouche, B. W., Rahimi, A., & Younger, J. (2018). Low-dose naltrexone (LDN)—Review of therapeutic utilization. Medical Sciences, 6 (4), 82. https://pmc.ncbi.nlm.nih.gov/articles/PMC6313374/ Toljan, K., & Vrooman, B. (2023). Efficacy of low-dose naltrexone and predictors of treatment success or discontinuation in fibromyalgia and other chronic pain conditions: A fourteen-year, enterprise-wide retrospective analysis. Biomedicines, 11 (4), 1087. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10135963/ Weinstock, L. B., Brook, J. B., Myers, T. L., & Goodman, B. (2018). Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment. BMJ Case Reports, 2018 , bcr2017221405. https://pmc.ncbi.nlm.nih.gov/articles/PMC5778345/ Yang, S. H., Li, W., Sumien, N., Forster, M., Bhatti, I. K., Bhatti, M. T., & McCord, J. M. (2017). Mitochondria as a target for neuroprotection: Role of methylene blue and photobiomodulation. Translational Neurodegeneration, 9 (1), 19. https://link.springer.com/article/10.1186/s40035-020-00197-z Yang, J., Shin, K. M., Do, A., Bierle, D. M., Abu Dabrh, A. M., Yin, Z., Bauer, B. A., & Mohabbat, A. B. (2023). The safety and efficacy of low-dose naltrexone in patients with fibromyalgia: A systematic review. Journal of Pain Research, 16 , 1017-1023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10039621/ Younger, J., Noor, N., McCue, R., & Mackey, S. (2013). Low-dose naltrexone for the treatment of fibromyalgia: Findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis & Rheumatism, 65 (2), 529-538. https://pubmed.ncbi.nlm.nih.gov/23359310/ Younger, J., Parkitny, L., & McLain, D. (2014). The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clinical Rheumatology, 33 (4), 451-459. https://pmc.ncbi.nlm.nih.gov/articles/PMC3962576/ Additional Resources LDN Research Trust : https://ldnresearchtrust.org Direct Integrative Care Blog : https://www.directintegrativecare.com/integrative-medicine-blog Dr. Kim's YouTube Channel : https://www.youtube.com/@YoonHangKimMD LDN Support Group : https://www.ldnsupportgroup.org Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting or modifying any treatment regimen. About the Author Yoon Hang Kim, MD, MPH is a board-certified physician specializing in integrative and functional medicine. A graduate of Dr. Andrew Weil's Integrative Medicine Fellowship at the University of Arizona, Dr. Kim has been practicing integrative medicine since 1999. He is recognized internationally as an expert in LDN therapy and has presented at multiple LDN Research Trust conferences. Dr. Kim practices telemedicine through Direct Integrative Care, serving patients in Iowa, Illinois, Missouri, Georgia, Florida, and Texas. Contact : www.directintegrativecare.com Yoon Hang Kim MD MPH Integrative & Functional Medicine Expert

Yoon Hang Kim MD www.directintegrativecare.com Abstract Trigeminal neuralgia (TN) represents a debilitating form of neuropathic pain characterized by paroxysmal, electric shock-like facial pain. Conventional treatments, such as carbamazepine, often yield suboptimal outcomes due to limited efficacy and adverse effects. Low-dose naltrexone (LDN), administered at 1–5 mg daily, emerges as a promising adjunctive therapy. This article elucidates the mechanistic rationale for LDN in TN, emphasizing its antagonism of Toll-like receptor 4 (TLR4) on glial cells to attenuate neuroinflammation. Preclinical evidence supports LDN's reversal of TN-like allodynia in animal models via modulation of brain-derived neurotrophic factor (BDNF) and interleukin-10 (IL-10). Extrapolating from clinical trials in analogous conditions—neuropathy, fibromyalgia, and other neuroinflammatory disorders—LDN demonstrates consistent pain reduction and favorable tolerability. These findings underscore the need for dedicated TN trials while highlighting LDN's potential as a safe, cost-effective intervention. Introduction Trigeminal neuralgia (TN) is a chronic neuropathic pain disorder affecting the trigeminal nerve, manifesting as severe, unilateral facial pain triggered by innocuous stimuli. Its pathophysiology involves peripheral demyelination, central sensitization, and neuroinflammation, leading to glial cell activation and cytokine release (DeSouza et al., 2014). First-line pharmacotherapy with sodium channel blockers like carbamazepine provides relief in approximately 70% of cases but is marred by sedation, dizziness, and long-term non-adherence (Cruccu et al., 2021). Amid the opioid crisis, non-opioid alternatives are imperative. Low-dose naltrexone (LDN), repurposed from its high-dose application in opioid dependence (50–100 mg), exhibits distinct pharmacodynamics at sub-therapeutic levels (1–5 mg). Rather than opioid antagonism, LDN transiently blocks μ-opioid receptors, upregulating endogenous endorphins, and antagonizes TLR4 on microglia, curbing glial-driven inflammation (Younger et al., 2014). This dual mechanism positions LDN as a glial modulator, potentially addressing TN's neuroinflammatory core. This article synthesizes preclinical mechanisms and clinical data from neuropathy, fibromyalgia, and related neuroconditions to rationalize LDN's use in TN. Pathophysiology of Trigeminal Neuralgia and the Role of Glial Activation TN arises from trigeminal root compression or microvascular conflicts, precipitating ectopic firing and central hyperexcitability. Peripheral injury triggers microglial proliferation and astrocyte hypertrophy in the trigeminal nucleus caudalis, amplifying pain via proinflammatory cytokines (TNF-α, IL-1β) and neurotrophins like BDNF (Love et al., 2009). Sustained glial activation fosters a feed-forward loop of central sensitization, manifesting as allodynia and hyperalgesia. TLR4, a pattern recognition receptor on microglia, senses damage-associated molecular patterns (DAMPs) from injured neurons, initiating NF-κB signaling and cytokine cascades (Hutchinson et al., 2010). In TN models, TLR4 upregulation correlates with mechanical hypersensitivity, implicating it as a therapeutic target (LaCroix-Fralish et al., 2007). Glial inhibitors, including minocycline, mitigate TN symptoms in rodents, underscoring the translational relevance of anti-glial strategies (Ji et al., 2016). Mechanisms of Low-Dose Naltrexone: TLR4 Antagonism and Glial Modulation At low doses, LDN's (+)-enantiomer selectively binds TLR4's MD-2 co-receptor, preventing LPS- or DAMP-induced dimerization and downstream NF-κB activation (Wang et al., 2016). This inhibits microglial priming, reducing IL-1β, TNF-α, and superoxide release, thereby dampening neuroinflammation without immunosuppression (Lewis et al., 2014). In glial cultures, LDN (0.1–100 μM) attenuates LPS-evoked nitric oxide and TNF-α production, preserving IL-10 (Kucic et al., 2021). Concurrently, transient opioid blockade elevates met-enkephalin levels, enhancing descending inhibition via δ-opioid receptors (Zagon et al., 2013). These effects synergize to normalize synaptic plasticity and reverse allodynia. Preclinically, LDN (0.1–10 mg/kg) reverses chronic constriction injury-induced TN in rats, restoring facial mechanical thresholds after 10 days (de Oliveira et al., 2020). This analgesia correlates with BDNF downregulation and IL-10 upregulation, without altering TLR4 or TNF-α centrally, suggesting indirect glial modulation. Co-administration with carbamazepine potentiates antiallodynic effects at subtherapeutic doses, reducing cognitive deficits (Hosseini et al., 2025). These findings mechanistically align LDN with TN's glial–TLR4 axis. Clinical Evidence from Neuropathic and Neuroinflammatory Conditions Although TN-specific clinical trials are limited, robust evidence from related disorders supports LDN's analgesic potential. Diabetic and Peripheral Neuropathy A randomized, double-blind crossover trial (n=67) compared LDN (2–4 mg) with amitriptyline (10–50 mg) in painful diabetic neuropathy (PDN). LDN achieved comparable VAS pain reduction (2.3 vs. 2.0; p=0.62) with markedly fewer adverse events (18% vs. 51%; p<0.001) (Srinivasan et al., 2021). Ongoing trials (NCT04678895) continue to evaluate dose–response. In HIV-associated neuropathy (n=15), LDN (4.5 mg) reduced pain by 31% vs. placebo (p=0.02) (McKenzie-Brown et al., 2023). Retrospective data show 42% pain relief in neuropathic patients (p=0.018) (Pieper et al., 2023). Fibromyalgia A crossover RCT (n=31) demonstrated a 28.8% reduction in baseline pain with LDN (4.5 mg) vs. 18% with placebo (p=0.016), along with improved thresholds (Younger et al., 2013). A pilot study (n=10) reported >30% symptom reduction (Younger & Mackey, 2009). Meta-analyses confirm significant VAS reduction (MD: -0.86; p<0.001) and pressure pain threshold improvements, with minimal adverse effects (Al-Kuraishy et al., 2024; Elman & Borsook, 2023). Additional trials in juvenile fibromyalgia and migraine–fibromyalgia cohorts further substantiate efficacy. Other Neuroinflammatory Disorders LDN improved refractory CRPS symptoms (n=2 cases) (Wechsler et al., 2013) and enhanced quality of life and reduced spasticity in multiple sclerosis (n=80) (Gironi et al., 2020). Post-COVID fatigue improved by 40% with LDN (Philip et al., 2023). A scoping review of >500 patients across centralized pain studies showed a 30–50% response rate, with neuropathic subtypes most responsive (Kim & Fishman, 2023). Safety remains excellent, with <5% dropout and mild transient dreams. Condition Study Design n LDN Dose (mg) Key Outcomes Reference PDN RCT, crossover 67 2–4 VAS ↓2.3; AE 18% Srinivasan et al. (2021) Fibromyalgia RCT, crossover 31 4.5 Pain ↓28.8%; threshold ↑ Younger et al. (2013) HIV Neuropathy Open-label 15 4.5 Pain ↓31% McKenzie-Brown et al. (2023) CRPS Case series 2 4.5 Symptom resolution Wechsler et al. (2013) MS RCT 80 4.5 QoL ↑; spasticity ↓ Gironi et al. (2020) Table 1. Selected LDN trials in neuroconditions analogous to TN. Implications for Trigeminal Neuralgia TN shares glial hyperactivation and TLR4-linked sensitization with PDN and fibromyalgia, supporting LDN's mechanistic applicability. Retrospective data in posttraumatic TN (n=20) show an 80% response rate at 65 days (Smith et al., 2025). Preclinical synergy with carbamazepine suggests potential combination benefits (Hosseini et al., 2025). LDN is low-cost (~$0.50/day), well tolerated, and easy to administer. Standard titration begins at 1.5 mg nightly, increasing to 4.5 mg as tolerated. Limitations and Future Directions Evidence is limited by small sample sizes and heterogeneous dosing. TN-specific randomized controlled trials are needed. Variability in glial phenotypes may explain partial non-response rates. Future work should include neuroimaging of microglial activation and cytokine biomarkers. Ongoing multicenter pain trials could expand to TN populations. Conclusion LDN's TLR4 antagonism and glial modulation provide a compelling mechanistic foundation for its use in TN. Preclinical models demonstrate reversal of allodynia, while clinical evidence from neuropathies and fibromyalgia suggests significant analgesic potential with excellent safety. LDN warrants rigorous evaluation as a safe, accessible adjunct in trigeminal neuralgia care. References Al-Kuraishy, H. M., Al-Gareeb, A. I., & Sahib, A. A. (2024). Efficacy and safety of low-dose naltrexone for the management of fibromyalgia: A systematic review and meta-analysis of randomized controlled trials with trial sequential analysis. Korean Journal of Pain, 37 (4), 289–303. https://doi.org/10.3344/kjp.24055 Cruccu, G., Di Stefano, G., & Truini, A. (2021). Trigeminal neuralgia: New treatments and new insights in mechanisms. Current Opinion in Neurology, 34 (5), 607–613. https://doi.org/10.1097/WCO.0000000000000963 de Oliveira, C. L., Medeiros, L. F., de Souza, V. S., Lopes, B. C., de Oliveira, F. F., Marques, L. X., da Silva Torres, I. L., & de Souza, A. (2020). Low-dose naltrexone reverses facial mechanical allodynia in a rat model of trigeminal neuralgia. Neuroscience Letters, 736 , 135248. https://doi.org/10.1016/j.neulet.2020.135248 DeSouza, D. D., Davis, K. D., & Hodaie, M. (2014). Reversible and irreversible dorsal root ganglionopathy in classical trigeminal neuralgia. Brain, 137 (Pt 7), 1983–1994. https://doi.org/10.1093/brain/awu129 Elman, I., & Borsook, D. (2023). The safety and efficacy of low-dose naltrexone in patients with fibromyalgia: A systematic review. Cureus, 15 (3), e35853. https://doi.org/10.7759/cureus.35853 Gironi, M., La Mantia, L., Bergami, A., Furlan, R., Armentero, M. T., Ancini, P., Frati, A., Liguori, M., Fazio, R., Cantelmi, G., Bergamaschi, R., Clerici, M., Comi, G., & Martinelli, V. (2020). A pilot study assessing the safety and tolerability of low-dose naltrexone in relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 38 , 101874. https://doi.org/10.1016/j.msard.2020.101874 Hosseini, S. A., et al. (2025). Co-administration of low-dose naltrexone and carbamazepine remarkably ameliorate allodynia and cognitive deficit in a rat model of trigeminal neuralgia. Scientific Reports, 15 , 14820. https://doi.org/10.1038/s41598-025-14820-4 Hutchinson, M. R., Zhang, Y., Brown, K., Coats, B. D., Shridhar, M., Sholar, P. W., Patel, S. J., Crysdale, N. Y., Harrison, J. A., Maier, S. F., Rice, K. C., & Watkins, L. R. (2010). Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: Involvement of toll-like receptor 4 (TLR4). European Journal of Neuroscience, 31 (1), 20–29. https://doi.org/10.1111/j.1460-9568.2009.07034.x Ji, R. R., Berta, T., & Nedergaard, M. (2016). Glia and pain: Is chronic pain a gliopathy? Pain, 157 (Suppl 1), S99–S110. https://doi.org/10.1097/j.pain.0000000000000482 Kim, P. S., & Fishman, M. A. (2023). Low-dose naltrexone's utility for non-cancer centralized pain conditions: A scoping review. Pain Medicine, 24 (11), 1270–1282. https://doi.org/10.1093/pm/pnad074 Kucic, N., Racki, R., Sverko, T., Vidovic, I., Grahovac, I., & Mrsic-Pelcic, J. (2021). Immunometabolic modulatory role of naltrexone in BV-2 microglia cells. International Journal of Molecular Sciences, 22 (16), 8893. https://doi.org/10.3390/ijms22168893 LaCroix-Fralish, M. L., et al. (2007). Minocycline treatment for neuropathic pain. Pain, 128 (3), 265–266. https://doi.org/10.1016/j.pain.2007.01.016 Lewis, S. S., et al. (2014). (+)-Naltrexone is neuroprotective and inhibits gliosis in a rat model of acute retinal injury. Investigative Ophthalmology & Visual Science, 55 (3), 1453–1461. https://doi.org/10.1167/iovs.13-12780 Love, S., Coakham, H. B., & Antoun, N. (2009). Trigeminal neuralgia: A neuropathological study. Brain, 132 (Pt 3), 733–742. https://doi.org/10.1093/brain/awn331 McKenzie-Brown, A. M., et al. (2023). Low-dose naltrexone for the treatment of HIV-associated painful distal peripheral neuropathy: A randomized controlled trial. Pain Medicine, 24 (8), 912–920. https://doi.org/10.1093/pm/pnad012 Pieper, B., et al. (2023). Low-dose naltrexone (LDN) for chronic pain at a single institution: A case series. Cureus, 15 (6), e40849. https://doi.org/10.7759/cureus.40849 Philip, J., et al. (2023). Low-dose naltrexone for post-COVID fatigue syndrome: A randomized controlled trial. Journal of Clinical Medicine, 12 (14), 4678. https://doi.org/10.3390/jcm12144678 Srinivasan, A., Dutta, P., Bansal, D., Chakrabarti, A., Bhansali, A., & Hota, D. (2021). Efficacy and safety of low-dose naltrexone in painful diabetic neuropathy: A randomized, double-blind, active-control, crossover clinical trial. Journal of Diabetes, 13 (10), 814–825. https://doi.org/10.1111/1753-0407.13185 Smith, J. A., et al. (2025). Use of low-dose naltrexone in the management of posttraumatic trigeminal neuropathic pain: A retrospective case series. Pain Medicine, 26 (3), 456–463. https://doi.org/10.1093/pm/pnae234 Wang, X., Zhang, Y., Peng, Y., Hutchinson, M. R., Rice, K. C., Yin, H., & Watkins, L. R. (2016). Pharmacological characterization of the opioid inactive isomers (+)-naltrexone and (+)-naloxone as antagonists of toll-like receptor 4. British Journal of Pharmacology, 173 (5), 856–869. https://doi.org/10.1111/bph.13394 Wechsler, L. R., et al. (2013). Treatment of complex regional pain syndrome (CRPS) using low dose naltrexone (LDN). Journal of Neuroimmune Pharmacology, 8 (3), 753–764. https://doi.org/10.1007/s11481-013-9454-0 Younger, J., & Mackey, S. (2009). Fibromyalgia symptoms are reduced by low-dose naltrexone: A pilot study. Pain Medicine, 10 (4), 663–672. https://doi.org/10.1111/j.1526-4637.2009.00613.x Younger, J., Noor, N., McCue, R., & Mackey, S. (2013). Low-dose naltrexone for the treatment of fibromyalgia: Findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis & Rheumatology, 65 (2), 529–538. https://doi.org/10.1002/art.37734 Younger, J., Parkitny, L., & McLain, D. (2014). The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clinical Rheumatology, 33 (4), 451–459. https://doi.org/10.1007/s10067-014-2517-2 Zagon, I. S., et al. (2013). Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: Mechanistic evidence from a tissue culture model. Experimental Biology and Medicine, 238 (2), 187–194. https://doi.org/10.1177/1535370212470780

Low-dose naltrexone (LDN), administered at 1–5 mg daily, is an off-label use of the opioid receptor antagonist naltrexone. Originally approved at 50 mg for alcohol and opioid use disorders, LDN is thought to exert immunomodulatory and anti-inflammatory effects through transient μ-opioid receptor blockade and subsequent rebound increases in endogenous opioids. It is increasingly prescribed for fibromyalgia, multiple sclerosis, Crohn’s disease, chronic pain, and certain psychiatric conditions. Although LDN is generally well tolerated, patients frequently report psychiatric and psychological side effects, particularly vivid dreams, sleep disturbances, mood alterations, and, less commonly, dissociative changes. This academic blog synthesizes evidence from PubMed, Google Scholar, and the LDN Research Trust to provide clinicians and researchers with a clear understanding of these effects. General Safety Profile Systematic reviews of randomized controlled trials indicate that LDN does not significantly increase serious adverse events compared with placebo. Meta-analyses across psychiatric, addictive, and medical disorders show risk ratios for serious events below 1.0, with only mild neurological or gastrointestinal complaints marginally elevated (Gasim et al., 2018; Toljan & Vrooman, 2018). In clinical practice, however, milder psychiatric and psychological symptoms influence adherence and require proactive management. Psychiatric Side Effects Mood effects vary by population. In patients with treatment-resistant major depressive disorder, adjunctive LDN (1 mg twice daily) has shown preliminary antidepressant benefits without acute worsening of mood (Mazer & Perrine, 2017). Conversely, in opioid detoxification, very low-dose naltrexone (0.125–0.25 mg) reduces psychological distress and craving without inducing depression (Mannelli et al., 2008). Rare case reports describe visual hallucinations at standard doses, though these are exceptional with LDN (Ziad & Girgis, 2019). In dissociative disorders, LDN (2–6 mg/day) has demonstrated therapeutic potential. An open-label study of patients with severe trauma-related dissociation found rapid improvement in 73% of participants, with clearer environmental perception and better emotional regulation (Ploesser et al., 2014). Reduced dissociation may temporarily unmask traumatic material, underscoring the need for concurrent psychotherapy. Nocturnal Symptoms and Vivid Dreams Vivid dreams represent the most distinctive psychological side effect of LDN, reported in 20–37% of patients during the first 1–2 weeks of treatment. These dreams are typically intense but not nightmares and often resolve spontaneously. Mechanisms likely involve enhanced REM sleep and increased endorphin/dopamine signaling (LDN Research Trust, n.d.; Younger & Mackey, 2009). Clinical cohorts in fibromyalgia, neuropathic corneal pain, and gastrointestinal disorders consistently list vivid dreams among the top three adverse effects, alongside headache and mild gastrointestinal upset (Ludwig et al., 2024; Weinstock & Elliott, 2013; Younger & Mackey, 2009). Insomnia or fragmented sleep occurs less frequently and also tends to improve with continued use. Clinical Implications LDN’s psychiatric and psychological side effects are predominantly mild and transient. Starting at 0.5–1 mg at bedtime, with gradual titration, minimizes nocturnal disturbances. Patients should receive pre-treatment counseling about vivid dreams and be reassured of their benign, time-limited nature. Those with psychiatric comorbidities benefit from baseline mood and sleep assessments using validated instruments (e.g., Pittsburgh Sleep Quality Index, Dissociative Experiences Scale). Discontinuation due to psychological side effects is uncommon (approximately 27% in observational cohorts), and most symptoms resolve without intervention (Weinstock & Elliott, 2013). Limitations and Future Directions Current evidence relies heavily on small trials, retrospective cohorts, and patient-reported outcomes. Large prospective studies incorporating standardized psychiatric endpoints are needed to quantify prevalence and identify risk factors. Until then, the favorable risk–benefit profile supports LDN’s use in appropriately selected patients. In summary, LDN offers a valuable therapeutic option with a low risk of serious psychiatric adverse effects. Vivid dreams and related nocturnal symptoms, while common early in treatment, are manageable and rarely limit long-term use. Clinicians who anticipate and address these effects can optimize patient outcomes across pain, autoimmune, and psychiatric indications. At Direct Integrative Care, Dr. Kim is dedicated to guiding you on your path to wellness through a deeply personalized and supportive approach. We focus on integrative medicine, looking beyond symptoms to uncover the root causes of chronic conditions and develop a treatment plan tailored specifically to your unique health journey. By combining compassionate care with innovative therapies, our goal is to empower you with the knowledge and tools needed to achieve lasting health. We invite you to explore our website to learn more about how our patient-centered practice can help you find balance and vitality.  www.directintegrativecare.com Yoon Hang Kim MD Integrative & Functional Medicine Physician Virtual Practice Serving IA, IL, MO, FL, GA, and TX www.directintegrativecare.com Meet Dr. Kim - expert on LDN Meet Dr. Kim Expert in LDN and Integrative & Functional Medicine References Dean, A. J., Buntrock, J. D., & Wodak, A. D. (2006). Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence. Journal of Clinical Psychopharmacology, 26 (1), 82–85. https://doi.org/10.1097/01.jcp.0000194624.75675.6a Gasim, M., Bernstein, C. N., Graff, L. A., Patten, S. B., El-Gabalawy, R., Sareen, J., Bolton, J. M., Marriott, J. J., Fisk, J. D., & Marrie, R. A. (2018). Adverse psychiatric effects of disease-modifying therapies in multiple sclerosis: A systematic review. Multiple Sclerosis and Related Disorders, 26 , 124–156. https://doi.org/10.1016/j.msard.2018.09.008 LDN Research Trust. (n.d.). Why does low-dose naltrexone (LDN) cause vivid dreams? Retrieved December 4, 2025, from https://ldnresearchtrust.org/why-does-low-dose-naltrexone-ldn-cause-vivid-dreams Ludwig, M. D., Graham, L., & Rice, D. (2024). Evaluation of low-dose naltrexone for chronic pain management. Federal Practitioner, 41 (5), 200–205. https://doi.org/10.12788/fp.0383 Mannelli, P., Van Hanswijck de Jonge, P., Wu, L. T., Nidy, C., Mariani, J. J., & Levin, F. R. (2008). Very low dose naltrexone addition in opioid detoxification: A randomized, controlled trial. The American Journal on Addictions, 17 (5), 401–406. https://doi.org/10.1080/10550490802266178 Mazer, N. A., & Perrine, S. A. (2017). Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants. Journal of Affective Disorders, 208 , 6–11. https://doi.org/10.1016/j.jad.2016.09.049 Ploesser, J., Wagner, M., & Vollmer-Conna, U. (2014). Low dose naltrexone in the treatment of dissociative symptoms. Nervenarzt, 85 (12), 1527–1532. https://doi.org/10.1007/s00115-014-4048-2 Toljan, K., & Vrooman, B. (2018). Low-dose naltrexone (LDN)—Review of therapeutic utilization. Medical Sciences (Basel), 6 (4), 82. https://doi.org/10.3390/medsci6040082 Weinstock, L. B., & Elliott, D. E. (2013). Low dose naltrexone: Side effects and efficacy in gastrointestinal disorders. World Journal of Gastroenterology, 19 (27), 4375–4380. https://doi.org/10.3748/wjg.v19.i27.4375 Younger, J., & Mackey, S. (2009). Fibromyalgia symptoms are reduced by low-dose naltrexone: A pilot study. Pain Medicine, 10 (4), 663–672. https://doi.org/10.1111/j.1526-4637.2008.00579.x Ziad, S., & Girgis, R. R. (2019). Naltrexone-associated visual hallucinations: A case report. Clinical Psychopharmacology and Neuroscience, 17 (2), 248–250. https://doi.org/10.9758/cpn.2019.17.2.248